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ABSTRACT 
 
The aim of this project was to investigate the anticancer activity of the anti-diabetic drug 
metformin, individually or combined in various settings with chemotherapy, on in vitro 
models of colorectal cancer (CRC). I found that metformin reduced cell proliferation by 
inducing cell cycle arrest in the G0/G1 phase, but did not lead to cell death. The anti-
proliferative action of metformin resulted mediated by the inactivation of the mTOR 
pathway and of IGF1R protein. However, the drug only transiently arrested cell growth, 
since its effects were reversed after drug removal.  
When I combined the biguanide with the chemotherapy drugs commonly used to treat 
CRC I observed different responses in the cell lines analysed that reflected their genetic 
background and their different sensitivities to both the biguanide and chemotherapy. I 
found that metformin added before chemotherapy drugs antagonised their effects in the 
majority of the treatments. On the contrary, its administration after long chemotherapeutic 
treatments significantly reduced the cell viability. I noted that metformin better inhibits cell 
proliferation in cell lines with rapid growth. 
I have also assessed the dual treatment combination of metformin with different drugs that 
target specific genes or proteins (targeted therapies), focusing on BRAF-mutant cell lines. 
For most of the tested treatments the simultaneous administration of metformin and target 
drugs gave no advantages over the single drugs, and often resulted in antagonism.  
Overall, our results show that although further investigations are still needed to elucidate 
the results of the treaments including metformin, these data suggest that caution should be 
used in administering chemotherapy to indviduals taking metformin.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Colorectal cancer  
Colorectal cancer (CRC) is the third most common worldwide cancer in men, 
after lung and prostate cancer, and the second in women, after breast cancer (Ferlay et al., 
2015). CRC is the fourth leading cause of cancer-related deaths with an estimated 
incidence of 1.4 million new cases and a mortality of >690,000 deaths annually. The 
incidence of the disease is influenced by several factors, such as geographical location and 
ethnicity (for example, African Americans are the racial group with the highest incidence 
of CRC in the United States and Ashkenazi Jews are the ethnic group with the highest risks 
of CRC; American Cancer Society), gender (incidence rate in men is higher by 35-40%) 
and age (more common in those over 50 years). The highest rates are found in Europe, 
North America, Japan and Oceania.  CRC is increasing rapidly in Latin America, Asia and 
Eastern Europe (Torre et al., 2016), reflecting the adoption in these countries of western 
lifestyles such as the intake of high-fat diets, physical inactivity and smoking. In the 
United States, Oceania and Europe the introduction of established screening tests that 
allow the early detection, and consequent removal, of precancerous lesions has decreased 
incidence of CRC. On the contrary, in Central America, South America and Eastern 
Europe, where screening procedures have not yet been adopted, CRC continues to 
increase. 
 
1.1.1 Risk factors for colorectal cancer 
Risk factors for CRC can be divided into modifiable, which are part of the diet 
and lifestyle (smoking, obesity, alcohol, physical inactivity and diabetes), and non-
modifiable, that include age, gender and genetic or hereditary factors.  
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Smokers and ex-smokers have an increased risk of incidence and mortality for CRC with 
respect to non-smoker individuals. Alcohol abuse appears to be related to alterations of 
mechanisms of DNA methylation, leading to changes in intestinal absorption, metabolism, 
and renal excretion of folates.  
As for obesity, in obese individuals the excess of adipose tissue can produce hormones 
such as insulin or oestrogens, which may promote carcinogenic mechanisms. The high 
consumption of fat and proteins (especially from animals), in particular the excessive 
consumption of red or processed meat, increases the risk of CRC. In contrast, a diet rich in 
fibers, mainly derived from fruits and vegetables, seems protective against CRC. Fibers 
can absorb faecal carcinogens, reduce faecal transit time and increase the production of 
short chain fatty acids (which increase the absorption of sodium and water in the colon), all 
processes associated with a lower risk of neoplastic transformation. Finally, a physically 
active lifestyle that improves immune functions, reduces inflammation and insulin levels 
diminishes CRC risk. Taken together, changes in diet and lifestyle integrated with 
preventive screenings represent potential prevention tools for CRC.  
As regards the non-modifiable risk factors, CRC incidence and death rates increase with 
age, and they are higher in men than in women (American Cancer Society).  
 
1.1.2 Histopathological characteristics of colorectal cancer 
The intestinal epithelium is formed by a one cell depth layer in many sites, and 
this population of cells is in constant flux to maintain homeostasis of cell renewal process, 
in which cell proliferation, differentiation and apoptosis of enterocytes is highly regulated 
both spatially and temporally (Senda et al., 2007). Epithelial cells are anchored on a 
basement membrane (basal lamina) that forms part of the extracellular matrix and is 
assembled from proteins secreted by both epithelial and stromal cells, mostly fibroblast, 
lying beneath the membrane. Other cell types including endothelial cells, which form the 
walls of capillaries, lymphatic vessels and immune cells are also present. Beneath this 
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layer of stromal cells there is a thick layer of smooth muscles responsible for intestinal 
peristalsis through periodic contractions (Weinberg 2007).  
Most of the pathological changes associated with the development of colon cancer occur in 
the epithelial layer, which undergoes transformation through a series of intermediate steps 
from carcinoma, where it is possible to observe a variety of tissue states with different 
degrees of abnormality, to mildly deviant tissues and high malignancy state, and later into 
multiple metastatic growths (Figure 1).  
 
Figure 1. Progression from polyp to cancer (modified from John Hopkins Medicine 
Colorectal Cancer http://www.hopkinscoloncancercenter.org). 
 
Focusing on the histopathological alterations of the colonic epithelium, there are some 
hyperplastic areas where epithelial cell proliferation is unusually high although the 
individual cells have normal phenotype. Other areas are characterized by growth with 
abnormal histologies and it is not possible to identify the well-ordered cell layer typical of 
the normal colonic epithelium and where the morphology of the individual cells is 
deviating from that of normal cells.  
During further stages of progression deviant growth that forms adenoma is observed 
(Weinberg 2007). All these forms are considered benign until they pass through the basal 
membrane and invade the underlying tissues and cells switch into a malignant direction 
and the deeper they penetrate into the stromal layers, the higher is the risk that they can 
migrate to anatomically distant sites in the body, and metastasize. 
 
 	 16 
1.1.3 Genetics of colorectal cancer 
About 70-75% of CRCs are sporadic (i.e. occurs following the acquisition of 
somatic mutations), and the remaining 20-25% can be familial (if the affected individuals 
are in close degree) or hereditary (if germline mutations are present and can be transmitted 
between generations). Hereditary factors that increase CRC risk include a personal or 
family history of CRC and/or polyps, a personal history of inflammatory bowel disease, 
and different inherited genetic conditions. About 5% of all CRCs present a hereditary 
origin, the most common types are Hereditary Non-Polyposis Colorectal Cancer (HNPCC, 
also named Lynch syndrome) and familial adenomatous polyposis (FAP). HNPCC, the 
most common form of hereditary colorectal cancer (3-4% of all cases), is an autosomal 
dominant disease caused by germline mutations in the DNA mismatch repair (MMR) 
genes, mainly MSH2 and 6, MLH1 and 3 and PMS1 and 2, leading to microsatellite 
instability (MSI; Fearon 2011).  HNPCC patients may also develop endometrial, ovarian, 
stomach, small intestine, pancreas, brain and upper urinary tract tumours. FAP is an 
autosomal dominant disease characterized by the development of hundreds to thousands of 
colonic adenomas (polyps) of different sizes that can evolve to CRC when not treated. FAP 
is caused by germline mutations in the tumour suppressor gene Adenomatous Polyposis 
Coli (APC) that regulates the degradation of β-catenin in the Wnt pathway. Loss of APC 
function increases the transcription of β-catenin target genes, including c-MYC, resulting in 
cell proliferation, which increases the probability of transformation of polyps into 
cancerous polyps. 
Familial CRC is probably related to inheritance, but the genetic loci responsible for the risk 
genotype are mainly unknown. It is likely to be caused by alterations in genes that are less 
penetrant, but more common that those associated with the familiar syndromes. 
Polymorphisms in genes that regulate metabolism or in genes regulated by environmental 
factors could be related to familiar predisposition to CRC. Sibling studies and studies with 
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parent/child pairs have estimated that up to 35% of all CRC cases can be attributed to 
genetic susceptibility (Lichtenstein et al., 2000).  
 
1.1.3.1 Vogelgram – a progression model for colorectal cancer 
The adenoma-carcinoma transition is a model of CRC development in which 
specific somatic mutations promoting tumorigenesis were acquired. Sporadic tumours can 
be caused by chromosomal instability (CIN, an unbalance in chromosome number 
provoked by amplifications or losses of chromosomal regions) present in 80-85% of cases 
of CRC, follow the model proposed by Fearon and Vogelstein (Vogelgram) according to 
which any transition from normal mucosa to carcinoma involves specific and well-defined 
alterations in oncogenes or tumour suppressor genes (Fearon et Vogelstein, 1990; Figure 
2).  
 
Figure 2. Vogelgram. Transformation of normal colon epithelium into malignant 
carcinoma by step-wise accumulation of genetic aberrations. Adapted from Markowitz and 
Bertagnolli 2009.  
 
The Vogelgram suggests that the adenoma to carcinoma sequence is initiated by alterations 
in the APC gene, followed by mutations in KRAS or BRAF genes, PI3KCA or PTEN, 
mutations or loss of TTP53 gene and of SMAD family member 4 (SMAD4).  
Two mutations in APC are required for the initiation of colorectal carcinogenesis, in 
agreement with the hypothesis of the "two-hits" of Knudson (Knudson, 1993). Loss of 
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APC gene, which also controls cell growth, leads to the formation of the typical small 
benign polyps. The best-known role of the APC protein is to regulate the levels of β-
catenin in the Wnt pathway, where APC is part of multi protein complex APC-axin-
GSK3β that interacts with β-catenin causing its phosphorylation, ubiquitination and 
consequent degradation in the proteasome (Barker, 2008; Figure 3 left panel). Mutations in 
APC gene prevent the formation of the APC-axin-GSK3β complex, allowing β-catenin to 
accumulate in the cytoplasm and then translocate to the nucleus. In the nucleus β-catenin 
can interact with several transcription factors of the T-Cell Factor Family, promoting the 
transcription of genes that regulate cell cycle and proliferation such as cyclin D and c-
MYC, and genes related to tumour progression as metalloproteinases MMP7 and MMP26 
(Figure 3 right panel). 
 
 
 
 
Figure 3. Wnt signalling pathway. In absence of Wnt ligand β-catenin can be 
phosphorylated for proteasome degradation (left panel). In the presence of Wnt ligand or 
of inactivating mutations on APC protein, Wnt signalling is activated and the oncoprotein 
β-catenin regulates genes involved in cancer progression (Fearon, 2011). 
 
Other mutations that lead to cancer progression are found in the KRAS and BRAF genes.  
In normal cells RAS and BRAF proteins are activated in response to extracellular signals 
and act as molecular switch in the cell proliferation, specifically by activating the MAPK 
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pathway. KRAS mutations, that constitutively activate the gene and cause adenomas 
progression, were detected in about 50% of CRCs, BRAF mutations in 5-10 % of CRCs.  
Other somatic mutations can occur in PI3KCA gene and lead to activation of PI3K 
signalling. The deregulation of this pathway can also occur after loss of the tumour 
suppressor gene PTEN that acts as inhibitor of PI3K signalling (Markowitz and Bertagnolli 
2009). 
The progression to carcinoma continues as a result of inactivation or loss of tumour 
suppressor gene TP53, which suppresses cell division or induces apoptosis in response to 
stress damage, driving progression to carcinoma (Kinzler and Vogelstein, 2002).  
Finally the loss of some genes mapping on chromosome 18q has an oncogenic effect in the 
gastrointestinal system (Taketo et al., 2000). Among the lost genes, DCC encodes for a 
transmembrane protein acting as receptor for netrins (factors involved in axonal guidance 
in the nervous system) involved in the regulation of apoptosis (Arakawa, 2004).  Other 
tumour suppressor genes on chromosome 18q are SMAD2 and SMAD4, which act as signal 
transducers in the Transforming Growth Factor β (TGF-β) signalling pathway 
(Montgomery et al., 2001). Moreover, inactivating mutations in the TGF-β type II receptor 
(TGFβIIR) are found in one third of CRCs (Markowitz et al., 1995). 
 
1.1.4 Colorectal cancer stem cells  
Stem cells, present in adult tissues, are characterised by self-renewal and multipotency. 
Lineage tracing experiments have shown that in the intestinal epithelium the stem cells 
reside at the bottom of the crypts (the base of glands) and symmetrically divide from a 
single clone (Winton et al., 1988); they are constantly renewed and migrate from the crypt 
base, towards the crypt-villus axis and (Snippert al al., 2010). Stem cells can be traced 
using endogenous molecular markers such as leucine-rich repeat (LRR)-containing G-
protein-coupled receptor 5 (Lgr5) gene they express (Barker et al., 2007; Figure 4). 
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Figure 4. Organization of the intestinal epithelium. The intestinal epithelium consists of 
repetitions of villus-crypt units (left panel). At the crypt base Lgr5 positive cells represent 
the stem component and are intercalated with Paneth cells. Lgr5-expressing stem cells lead 
to the production of highly proliferative progenitors of differentiated cells that migrate 
along the crypt-villus axis (right panel). Adapted from de Lau et al., 2014. 
 
 
The identification of Lgr5 positive cells as intestinal stem cells was provided by in vivo 
Lgr5-based lineage tracing experiments (Barker et al., 2007). Through this technique 
candidate stem cells are marked and the cells descendants, inheriting the same marker, can 
be visualised. Because the marker was present in all epithelial cells, Lgr5-positive cells 
have been established as self-renewing and multipotent population of adult intestinal stem 
cells. Moreover it was demonstrated that single Lgr5-positive cells can generate and 
maintain the stem-cell hierarchy in in vitro matrigel culture systems (Sato et al., 2009). 
Lgr5 is encoded by a Wnt target gene and constitutes a facultative component of the Wnt 
receptor complex (de Wetering et al., 2002, de Fllier et al., 2007, de Lau et al., 2011).  The 
Wnt signalling plays indeed a pivotal role in stem cells maintenance and its deregulation in 
the stem compartment can lead to adenoma formation (Barker et al., 2009).  
Other well established CRC stemness markers are CD133 and CD44, both related to Wnt 
pathway: CD133 positive cells express high levels of β-catenin (Kawamoto et al., 2010) 
and CD44 is a gene targeted by β-catenin (Wielenga et al., 1999).  
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CD133 is a transmembrane glycoprotein with yet unclear function. In CRC it can promote 
tumour growth with self-renewal capability (O’Brien et al., 2007, Ricci et al., 2007). CD44 
is a transmembrane glycoprotein involved in cell-cell and cell-matrix interaction (Sahlberg 
et al., 2014). Dalerba et al. demonstrated that in human CRC xenografts, tumours derived 
from CD44 positive cells maintained a differentiated phenotype and reproduced the 
morphology and phenotype of their parental lesions (Dalerba et al., 2007). 
 
1.1.5 Colorectal cancer stages 
The classification of cancer lesions is the most important prognostic predictor of 
the clinical outcome in patients with CRC. The staging system used for CRC is the 
American Joint Committee on Cancer (AJCC) TNM system. The TNM system is based on 
tumour infiltration degree and discriminates to which of the intestinal wall layer tumour 
has arrived (T), if it has spread to regional lymph nodes (N) and/or it has invaded other 
organs resulting in metastases (M; American Cancer Society). 
The transition from carcinoma in situ (Tis), in which the tumour does not exceed the 
lamina propria, to stage T1 invasive carcinoma occurs when the tumour comes to the 
submucosa. Following the sequential invasion of muscularis and subserosal mucosa, the 
progression to the next stages T2 and T3 happens. Finally, the T4 stage occurs when the 
cancer invades other organs and / or perforates visceral peritoneum (Figure 5).   
 
Figure 5. Stages of colorectal cancer. Image from National Institute of Health (NIH) and 
National Cancer Institute (NCI). 
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The detection of any positive lymph node is critical to predict the outcome of patients. It is 
therefore necessary to examine an adequate number of regional lymph nodes (at least 7-
14). The TNM staging system for lymph nodes start from N0, classification for which the 
lymph nodes are metastases free. In N1 stage metastases are detected in 1-3 lymph nodes, 
in N2 metastases are found in 4 or more regional lymph nodes. Although CRC can 
metastasize in almost all organs, the liver and the lungs are the most common sites but it is 
usual to detect metastases in other segments of the colon, small intestine and peritoneum. 
The TNM staging for metastases has M0 and M1 values, indicating the presence or 
absence of metastases respectively. The TNM categories are combined in stage groups, 
ranging from 0 (in situ tumour) to IV (distant metastasis; Table 1). 
 
Table 1. TNM staging of colorectal cancer 
TNM stage T N M 
0 Tis N0 M0 
I T1- T2 N0 M0 
IIA T3 N0 M0 
IIB T4 N0 M0 
IIIA T1-T2 N1 M0 
IIIB T3-T4 N1 M0 
IIIC any T N2 M0 
IV any T any N M1 
 
The staging degree is inversely proportional to the probability of survival. In fact, the 
survival rate at 5 years passes from 75-80% in individuals with stage I diagnosis to 15% in 
individuals with stage IIIC diagnosis (Gunderson et al., 2010). In stage IV the 5-year 
survival after diagnosis is less than 5%. 
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1.1.6 Treatments for Colorectal Cancer 
Four key approaches are currently used for the treatment of CRC: surgery, 
chemotherapy, radiotherapy and targeted therapies. Treatment for colon cancer is based 
largely on the stage (extent) of the cancer, and people with early stage disease (stage I and 
II) usually have surgery as the main or first treatment, in some cases followed by adjuvant 
chemo or radiation therapies. Adjuvant therapy is the standard of care for patients with 
stage III disease, which have a high survival benefit. Patients with metastatic disease (stage 
IV) require chemotherapy or targeted therapies combined with surgery, where appropriate.  
 
1.1.6.1 Chemotherapy  
Chemotherapeutic agents include fluoropyrimidines (5-Fluorouracil (5-FU) and 
capecitabine), oxaliplatin and irinotecan (Meyerhardt et Mayer, 2005, Koopman et al., 
2007, Seymour et al., 2007, Kelly and Cassidy 2007). 
5-FU remains the most widely used chemotherapeutic agent for the treatment of CRC. 
Following metabolic activation to 5-fluoro-2′-deoxyuridylate, this fluorinated pyrimidine 
combines with methylenetetrahydrofolate to form a ternary complex with thymidylate 
synthase, an enzyme involved in pyrimidines synthesis, thus interfering with DNA 
synthesis by inhibiting the conversion of deoxyuridylate to thymidylate. 5-FU is often 
given with Leucovirin (LV, also called folinic acid) to improve the effect of the 
chemotherapy drug. Capecitabine is a precursor of 5-FU that is converted to 5-FU through 
three sequential enzymatic reactions. The final enzyme in the pathway, thymidine 
phosphorylase (TP), is believed to be present at very high levels in tumour tissue, thus 
increasing both the efficacy and tolerability of the agent through targeted delivery. 
Oxaliplatin, a platinum analogue, forms intra- and inter-strand DNA adducts, leading to 
inhibition of DNA replication and transcription.  
Irinotecan is a semi-synthetic derivative of the natural alkaloid camptothecin, which 
inhibits the activity of Topoisomerase I, a nuclear enzyme involved in DNA synthesis. 
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During DNA replication, Topoisomerase I relaxes the supercoiled DNA helix with 
reversible and transient single-stranded DNA breaks. The active metabolite of irinotecan 
(SN-38) stabilizes the DNA–topoisomerase complex, resulting in replication arrest and 
apoptosis. 
Current international guidelines (National Comprehensive Cancer Network, NCCN) 
suggest the use of these chemotherapy agents alone or in combinations (NCCN guidelines 
2015). According to NCCN guidelines the drugs, to increase their effectiveness, can be 
combined in the following regimens: FOLFOX (5-FU/LV/oxaliplatin), FOLFIRI (5-
FU/LV/irinotecan), CapeOx (Capecitabine/oxaliplatin) and FOLFOXIRI (5-
FU/LV/oxaliplatin/irinotecan). In fact, patients treated with regimens seem to have an 
increase in overall survival (OS) and in progression free survival (PFS), compared with 
patients treated with single chemotherapeutic agents (Rodrigues et al., 2016, Doullard et 
al., 2000, Grothey et al., 2004).  
 
1.1.6.2 Targeted therapies for colorectal cancer 
Targeted cancer therapies include drugs or other substances that block the growth 
and spread of cancer by interfering with specific molecules ("molecular targets") that are 
involved in the growth, progression and spread of cancer. Targeted therapies are often 
cytostatic. Used alone or in combination with chemotherapy, these therapies have been 
proven to increase the OS in patients with metastatic CRC (mCRC). Many targeted cancer 
therapies have been approved by the Food and Drug Administration (FDA) to treat specific 
types of cancer. As for mCRC, the current FDA-approved targeted therapies can be 
divided into three groups: inhibitors of angiogenesis targeting Vascular Endothelial 
Growth Factor (VEGF) or its receptors, monoclonal antibodies (mAbs) against Epidermal 
Growth Factor Receptor (EGFR) and inhibitors of kinases involved in various signalling 
cascades [VEGF receptors, RET, KIT, Platelet Derived Growth Factors Receptor 
(PDGFR), and Raf kinases]. Others are being studied in clinical trials, and many more are 
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in preclinical testing.  
VEGF is the most important factor regulating tumour angiogenesis (Ferrara et al., 2003). 
The drug developed to inhibit the VEGF signalling processes is Bevacizumab, a 
recombinant humanised mAb that specifically targets circulating VEGF-A, which is 
synthesised during tumour growth. Bevacizumab prevents VEGF from interacting with 
appropriate receptors in vascular endothelial cells, resulting in diminished cell signalling 
pathways that enhance angiogenesis (Ferrara et al., 2004). The mAb, when administered in 
combination with chemotherapy increases the activity of any active cytotoxic regimen and 
improves OS, response rate (RR) and PFS in patients with mCRC (Saltz et al., 2008, 
Bennouna et al., 2013). 
Cetuximab and panitumumab are two EGFR antagonists, chimeric and fully humanized 
mAbs respectively. Both antibodies prevent EGFR auto-phosphorylation by binding to the 
extracellular domain and thus inhibiting activation of the downstream cell signalling 
pathways of MAPK and PI3K/Akt involved in proliferation and cell survival respectively 
(Ciardiello and Tortora 2008). Cetuximab and panitumumab are active in different lines of 
treatment and in various combinations and patients treated with anti-EGFR mAbs 
administered with FOLFOX or FOLFIRI regimens show a significantly improved RR, OS 
and PFS (Venook et al., 2006, Douillard et al., 2010, Bokemeyer et al., 2014). However 
their benefit, either as a single agent or in combination with any chemotherapy regimen, is 
limited to patients in whom a RAS mutation is excluded. KRAS oncogenic mutations, seen 
in 35-45% of CRCs, occurring prevalently in the codons 12 and 13 of exon 2, exclude 
patients from cetuximab/panitumumab therapies. In fact, the anti-EGFR drugs are 
currently indicated only in patients with wild type RAS (Lievre et al., 2006, De Roock et 
al., 2010, Van Cutsem et al., 2015). An ‘expanded RAS’ analysis that also includes 
additional mutations in exons 3 and 4 of the KRAS gene and in exons 2–4 of NRAS gene 
that reduce the efficacy of anti-EGFR treatments has improved the efficacy of the 
treatment (Bokemeyer et al., 2014).  
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Regorafenib is a multikinase inhibitor that blocks the activity of multiple protein kinases 
involved in the regulation of angiogenesis (VEGFR-1, -2, -3, angiopoietin-1 receptor), 
oncogenesis (KIT, RET, BRAF, including BRAF V600E) and of tumour 
microenvironment (PDGFR-β, Fibroblast growth factor receptor (FGFR; Wilhelm et al., 
2011). In patients with mCRC refractory to standard chemotherapy, treatment with 
regorafenib increased median RR, OS and PFS (Grothey et al., 2013). 
 
1.1.6.2.1 New targeted therapies for colorectal cancer 
Although patients are eligible for the therapies described, not all respond to them. 
To fill up this gap, increasing new targeted therapies for CRC are emerging, concurrently 
to the identification of biological markers that can predict the response to therapy. 
BRAF, involved in EGFR signalling, is mutated in 5-10% of CRC (Tol et al., 2009). The 
most common mutation V600E leads to constitutively activation of the kinase protein, 
conferring a very poor prognosis. Clinical results with the selective BRAF V600E inhibitor 
vemurafenib as single agent in CRC have been disappointing, although the inhibitor is very 
effective for melanoma treatment (Flaherty et al., 2010, Chapman et al., 2011, Sosman et 
al., 2012, Kopets et al., 2015). It has been observed that in CRC the inhibition of BRAF 
V600E caused a rapid feedback activation of the EGFR signalling pathway, through ERK 
activation, which is inhibited in melanoma. Therefore, combinatorial treatments with 
BRAF V600E and EGFR inhibitors appear a rational strategy and already seem to provide 
clinical benefits (Corcoran et al., 2012, Prahallad et al., 2012, Yaeger et al., 2015, Elez et 
al., 2015, Van Cutsen et al., 2015).  
Recently, other BRAF mutations have been found at codons 594 or 596, which occur in 
<1% of CRCs. These mutations identify a molecular subtype unexplored with clinical and 
pathological features different from BRAF V600E mutated cases and characterised by a 
longer OS.  BRAF 594 and 596 mutations cause only modest and indirect activation of the 
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MAPK pathway and preclinical and clinical data are suggestive of their potential 
sensitivity to anti-EGFR treatment (Cremolini et al., 2015). 
Much attention has recently been directed to the inhibition of downstream components of 
the RAS/RAF/MAPK/MEK/ERK pathway. Different MEK 1/2 inhibitors, such as 
trametinib, and selumetinib, have already been approved for the treatment of mCRC. MEK 
inhibitors alone do not seem to be effective, but their combination with BRAF inhibitors 
can produce clinical benefits in metastatic patients with mutations in BRAF (Corcoran et 
al., 2015). 
Other novel therapies in clinical development, targeting different pathways involved in 
cancer progression such as MET, mammalian target of rapamycin (mTOR), Wnt etc. are 
being developed and are summarised in Table 2 (Seow et al., 2016). 
 
Table 2. Targeted therapies in clinical development for colorectal cancer. 
Target gene Type of drug 
IGF1R Dalotuzumab, Cixutumumab 
MET Tivantinib 
PI3K BKM120 
mTOR PF-05212384 
Wnt pathway OMP-18R5, OMP-24F28, PRI-724, WNT974 
NOTCH R04929097, PF-03084014 
Sonic HedgeHog Vismodegib 
 
1.1.6.3 New frontiers: immunobased therapies 
Immunotherapy approaches based on the exploitation of the immune system to 
treat cancer, have recently yielded various degrees of success to treat certain tumor types, 
including melanoma, lung and kidney. These approaches exploit the fact that cancer cells 
often have molecules on their surface (including PD-1/PD-L1 and CTLA-4/B7-1/B7-2) 
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that can be detected by the immune system and prevent immune T cells from killing 
cancer. When these proteins are blocked, T cells are able to kill cancer cells better. As 
shown by Le et al. in CRC immunotherapy seems to be effective only in the subset of 
MSI-high tumours that present an increased mutational load due to DNA mismatch-repair 
deficiencies that stimulates the immune system. Indeed, patients with mismatch repair-
deficient CRC had better clinical response to PD-1 blockade by pembrolizumab than those 
whose CRC did not have mismatch-repair deficiencies (Le et al., 2015). 
 
1.2 Metformin  
The biguanide metformin (1,1-dimethylbiguanide hydrochloride) is a widely 
prescribed oral anti-hyperglycaemic agent used as first line treatment for patients with type 
2 diabetes mellitus. In diabetic patients metformin can reduce the hepatic gluconeogenesis 
and increases glucose uptake and use in skeletal muscle. Compared to other anti-diabetic 
drugs metformin is well tolerated, it does not induce hypoglycaemia and has a low risk of 
causing lactic acidosis. Metformin is also used to treat polycystic ovarian syndrome, 
metabolic syndrome and for diabetes prevention (Pierotti et al., 2013).  
 
1.2.1 Metformin as anticancer drug 
Different retrospective studies showed that patients with type 2 diabetes treated 
with metformin have lower cancer incidence and/or reduced cancer mortality (Evans et al., 
2005, Libby et al., 2009, Noto et al., 2012, Zhang et al., 2013), focusing the interest in 
metformin as anticancer agent. The mechanisms through which metformin seems to 
promote anticancer effects can be either indirect or systemic, that modulate metabolic 
whole body physiology, or direct, which acts directly on cancer cells inhibiting cancer 
progression. 
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1.2.1.1 Indirect or systemic effects of metformin on cancer cells 
The liver, exposed to high levels of the drug after oral administration, is 
considered the main target organ of metformin. In fact, hepatocytes express high levels of 
the cell surface organic cation transporter 1 (OCT1), necessary for the active transport of 
metformin (which is positively charged) into the cells (Gong et al., 2012). Inside the cell, 
mitochondria seem to be the primary target of metformin (El-Mir et al., 2000), in which 
the drug inhibits the respiratory complex I causing reduction of the synthesis of ATP and 
oxidation of NADH. The depletion of ATP production and the concomitant increase in the 
levels of AMP induces the activation of the cell energy sensor 5’-AMP-activated protein 
kinase (AMPK; Zhou et al., 2000). When activated, AMPK down-regulates the processes 
that require ATP, such as protein synthesis, and promotes catabolic pathways that generate 
ATP. This energy stress leads to a decrease of hepatic gluconeogenesis (Minassian et al., 
1998) with a consequent reduction of the circulating glucose and insulin levels. The 
reduction of haematic levels of glucose is also a consequence of increase of sugar uptake in 
skeletal muscle caused by the metformin-induced membrane translocation of the glucose 
transporter GLUT-4 specifically expressed in this tissue (Fischer et al., 1995). Because 
elevated serum levels of insulin and insulin-like growth factor-1 (IGF-1) are often 
necessary to sustain the growth and survival of cells in different cancer types, the systemic 
reduction of these hormones can impair malignant growth (Pollak, 2012; Figure 6). 
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Figure 6. Antineoplastic mechanisms of action of metformin. Metformin indirect (left) 
and direct (right) effects are shown. Adapted from Daugan et al., 2016. 
 
1.2.1.2 Direct effects of metformin on cancer cells  
The direct anticancer effects of metformin can be differentiated in AMPK-
dependent and AMPK-independent. AMPK can be directly activated by the previously 
described increase of AMP/ATP ratio, or indirectly, through its upstream regulator 
serine/threonine liver kinase B1 (LKB1; Woods et al., 2003). The activated form of AMPK 
suppresses the mammalian target of rapamycin (mTOR) pathway either through the 
phosphorylation and activation of tuberous sclerosis complex 2 (TSC2) that in turn inhibits 
the mTOR activator Rheb (Inoki et al., 2003) or by phosphorylation of Raptor, a positive 
regulator of mTOR (Gwinn et al., 2008). The block of mTOR inhibits the activation of its 
downstream target 40S ribosomal protein subunit S6 kinase (S6K or S6) and of the 
translational repressor 4E-binding protein 1 (4E-BP1), inactivated by mTOR mediated 
phosphorylation (Pierotti et al., 2013; Figure 7).  
Metformin can also inhibit mTOR signalling independently from AMPK activation by 
suppressing the Ragulatory complex, consisting of the RAG family of GTPases (Kalender 
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et al., 2010), or by activating the negative regulator of mTOR regulated in development 
and DNA damage responses 1 (REDD1; Ben Sahra et al., 2011; Figure 7). 
 
Figure 7. Metformin mechanisms of actions. AMPK dependent mechanisms are marked 
as red lines, AMPK-independent mechanisms as blue lines. Adapted from Pierotti et al., 
2013.  
 
The inhibition of protein synthesis via mTOR is only one of the mechanisms by which 
metformin can reduce cancer growth (Figure 6). Metformin exerts an inhibitory effect on 
glucose metabolism; in fact it can revert the Warburg effect, present in most cancer cells, 
either through the decrease of the glycolytic enzyme hexokinase 2 (HK2; Salani et al., 
2014) or through the suppression of oncogenes such as c-Myc, Akt and hypoxia-inducible 
factor 1 α (HIF-1α that support the glycolytic phenotype (Daugan et al., 2016). The 
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metformin-induced AMPK activation can reduce enzymes involved in fatty acids 
biosynthesis as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), reducing 
energy supply and counteracting tumour progression (Algire et al., 2010, Lettieri et al., 
2014). The biguanide can also promote cell cycle arrest through AMPK-mediated 
activation of TP53 and reduction of cyclin D1 expression (Ben Sahra et al., 2008, Zhuang 
et al., 2008, Alimova et al., 2009, Fujihara et al., 2015). It has also been reported that 
metformin can reduce the risk of mutagenesis in cancer cells, that can be escaped either by 
the inhibition of reactive oxygen species (ROS) in the mitochondria production or through 
the activation of ataxia telangiectasia mutated (ATM) protein, a tumour suppressor 
involved in DNA repair (Algire et al., 2012, Vazquez-Martin et al., 2011). Metformin can 
also inhibit the inflammatory signalling that promotes carcinogenesis by suppressing 
different pro-inflammatory cytokines such as tumour necrosis factor αTNF-α, nuclear 
factor kappa B (NF-κB) and interleukin 6 (IL-6; Takemura et al., 2007, Hirsch et al., 
2013). The anti-angiogenetic effect of metformin is linked to reduction of the main factors 
involved in vascular remodelling such as VEGF and HIF-1α (Joe et al., 2015, Tadakawa et 
al., 2015). Finally it was also observed that metformin treatment can selectively target 
cancer stem cells (CSCs), a tumour sub-population characterised by self-renewal capacity, 
resistance to chemotherapy and increase in cancer recurrence (Hirsch et al., 2009, 
Vazquez-Martin et al., 2010, Song et al., 2012, Bao et al., 2012, Shank et al., 2012, Hirsch 
et al., 2013, Kim et al., 2014). 
 
1.2.2 Metformin in CRC 
Several studies have shown that metformin can be used for the treatment of CRC. 
Epidemiological evidences showed that patients with type 2 diabetes taking metformin had 
a lower risk of cancer incidence when compared with patients treated with other anti-
diabetic drugs (Libby et al., 2009, Zhang et al., 2011, Garrett et al., 2012, Lee et al., 2012, 
Spillane et al., 2013). In vitro studies demonstrated that metformin can inhibit the 
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proliferation of CRC cells through AMPK activation (Zakikhani et al., 2008). In vivo 
models showed that metformin suppressed the development of intestinal polyps in in APC 
Min/+ mice, a model of FAP (Tomimoto et al., 2008) and also inhibited the formation of 
intestinal aberrant crypt foci in a chemical carcinogen-induced mouse model (Hosono et 
al., 2010). Buzzai et al. demonstrated that metformin can selectively inhibit tumour growth 
and increase apoptosis in a mouse model of TTP53 deficient CRC (Buzzai et al., 2007). 
Finally, Algire et al. showed that in mice fed with a high-energy diet metformin inhibited 
the growth of colon carcinomas and reduced insulin levels (Algire et al., 2010).  
As regards the risk to develop CRC in non-diabetic patients, Hosono et al. demonstrated 
that the short term treatment with metformin administered at low doses (250 mg/day) 
suppressed the formation of rectal aberrant crypt foci (a surrogate marker for CRC) and 
decreased the proliferation of the colonic epithelium (Hosono et al., 2010). 
Different studies combined metformin with other drugs in CRC. Nangia-Makker et al. 
demonstrated that metformin in combination with 5-FU and oxaliplatin promotes cell death 
in chemotherapy resistant CRC cell lines and inhibits their growth in an in vivo model 
(Nangia-Makker et al., 2014). Another study reported that combined treatment with 
metformin and 5-FU can reduce cell proliferation in chemo resistant CRC cell lines (Corti 
et al., 2015). Li et al. reported that combined use of metformin and vitamin D3 exerts a 
chemo-preventive effect reducing the number of rectal aberrant crypt foci in mice and rats 
(Li et al., 2015). Metformin in combination with 5-aminosalicylic acid increased apoptosis 
and inhibited inflammatory and metastatic pathways in CRC cell lines (Saber et al., 2015). 
Finally several clinical trials combining metformin with chemotherapy drugs are ongoing, 
for example: metformin plus irinotecan for refractory CRC (NCT01930864), metformin 
and 5-FU for refractory CRC (NCT01941953) and metformin in association with 
chemoradiotherapy for locally advanced rectal cancer (NCT02473094; Zhang et al., 2016). 
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CHAPTER 2 
AIM OF THE STUDY 
 
The aim of this thesis was to investigate the possible anticancer activity of metformin in in 
vitro models of CRC. In fact, although previous studies have shown that the drug inhibits 
the proliferation of CRC cells, its underlying mechanisms of action on CRC are still 
unclear. 
I initially investigated the effects of metformin on four CRC cell lines characterized by 
different mutations at LKB1, BRAF, KRAS and TP53 genes, and on 3D-organoids derived 
from a patient’s peritoneal carcinomatosis. I evaluated: the proliferative potential of cells 
undergoing metformin treatment, changes in the expression of CRC stemness markers, cell 
cycle modifications, activation of modes of cellular death that could be induced by the 
drug, clonogenic capacity of the cells after metformin treatment and changes in the main 
biochemical pathways that could be targeted by the drug. 
Then I studied the effects of metformin in combined settings with the standard 
chemotherapeutics drugs used in CRC: 5-FU, oxaliplatin and irinotecan. In particular I 
assessed if any combination of the biguanide with chemotherapeutic drugs could overcome 
the transient effect of metformin on cell proliferation I observed in the first part of the 
project. 
Finally, I analyzed the biochemical effects of metformin and changes in the cell cycle in 
combination with different targeted drugs on BRAF-mutant CRC cell lines. BRAF-mutant 
tumours are characterised by a high proliferation rate, poor sensitivity to standard 
treatments, early development of resistance to targeted therapies and worse prognosis. 
Among the new therapeutic approaches, the combination of novel therapies for CRC with 
regulators of metabolism seems to be a promising strategy, to overcome resistance to the 
targeted therapies in BRAF-mutant CRC. For this reason, I studied the effects of the 
combination of metformin with targeted drugs on BRAF-mutant cell lines. 
TRANSLATION 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Genetics characteristics and culture conditions of the colorectal 
cancer cell lines  
The cellular models used for the analysis of the effects of metformin in CRC were four cell 
lines characterised by different mutations frequently identified in CRC at BRAF, KRAS and 
TP53 genes (all involved in CRC progression) and at LKB1 gene (the main AMPK 
activator). HCT116P53-/- cells derived from the HCT116 cell line and carry a deletion of 
the region of chromosome 17 where TP53 gene maps. The specific genetic features of the 
cell lines are summarised in Table 3. 
 
Table 3. Genetic characteristics of the cell lines 
 LKB1 BRAF KRAS TP53 
HT29 WT V600E WT R273H 
HCT116 partially methylated WT G13D WT 
HCT116P53-/- partially methylated WT G13D null 
DLD-1 methylated WT G13D S241F 
 
The analysis of the effects of metformin combined with the standard regimens was 
conducted on HT29 cells and on the two HCT116 cell lines. 
Finally, three BRAF-mutant cell lines, differing for the type o BRAF mutation or for their 
mismatch repair activity, were used for the studing metformin in combination with the 
targeted therapies (Table 4). BRAF tumours carrying the common V600E mutation display 
a more aggressive phenotype than tumours with the rare G596R mutation. Indeed 
differences in MSI status seem to be associated with a different response to the therapies. 
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Table 4. BRAF and MSI status of the cell lines  
 BRAF MSI 
HT29 V600E MSS 
RKO V600E MSI 
NCI-H508 G596R MSS 
 
The cell lines HT29, HCT116, DLD-1, RKO and NCI-H508 were obtained from the 
collection available at IFOM (Istituto FIRC di Oncologia Molecolare, Milano). The 
HCT116P53-/- isogenic cell line, in which the TP53 gene was inactivated by homologous 
recombination, was kindly provided by Professor Bert Vogelstein (Johns Hopkins 
University, Baltimore, USA).  Each cell line was grown in a specific medium: HT29, 
HCT116 and HCT116P53-/- cell lines in McCoy's 5A medium (Modified) GlutaMAXTM 
Supplement (Gibco) + 10% fetal bovine serum + 1% Penicillin-Streptamycin (Gibco); 
DLD-1 cells in RPMI (Gibco) + 10% fetal bovine serum + 1% Glutamine + 1% Penicillin-
Streptamycin; RKO cells in MEM (Gibco) + 10% fetal bovine serum + 1% NEAA (MEM 
Non Essential Amino acids) + 1% Sodium Pyruvate + 1% Penicillin-Streptamycin; NCI-
H508 cells in RPMI + 10% fetal bovine serum + 1% Glutamine + 1% Penicillin-
Streptamycin. All cells were maintained as a monolayer in a humidified incubator at 37°C 
with a supply of 5% CO2.  
 
3.2 MTT viability assay  
To test the cell viability, CRC cell lines were seeded into a 96 well plate (1500 - 
3000 cells per well) in six replicates. After 24 hours cells were exposed to different 
concentrations of drugs: 0.16 - 20 mM for metformin (Sigma Aldrich); 0.3 - 64 µM for 5-
FU (TEVA); 0.064 - 8 µM for oxaliplatin (Fresenius Kabi); 0.004 - 4 µM for 
irinotecan/SN-38 (Sigma Aldrich); 30 nM – 100 µM for dasatinib and regorafenib 
(Selleckchem); 0.007 nM – 0.12 µM for trametinib (Selleckchem); 7.75 nM - 20 µM for 
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vemurafenib (Selleckchem); 0.003 nM – 10 µM for panitumumab (Amgen). After the time 
points set for each experiment (72 hours for detection of the Inhibitory Concentration 50 
(IC50) and of the best concentrations combination of drugs; 96 – 144 hours for the 
sequential treatments with chemotherapy drugs) the cell proliferation rate was measured 
using an MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, a 
colorimetric test for measuring the activity of enzymes produced by viable metabolically 
active cells that reduce MTT substrate to formazan, giving a purple colour. MTT powder 
(Sigma) was dissolved in the growth medium at the concentration of 1 mg/2 ml. After 
removal of the original medium, 100 µl of MTT solution were added to each well and 
incubated at 37°C. After two-three hours 100 µl of lysis buffer (10% SDS, HCl 0.01 M) 
was added to the MTT solution to dissolve the formazan crystals. Plates were then re-
incubated at 37°C overnight under light protected conditions and the following day were 
read on a micro-plate reader (Infinite M200 TECAN) at a wavelength of 570 nm. 
 
3.3 Colorectal cancer organoids derived from a peritoneal carcinomatosis  
Organoids were derived from a peritoneal carcinomatosis  (pc) obtained from a metastasis 
of a patient with stage IV, grade 3 CRC (a written informed consent to donate the tissues 
left over after the diagnostic procedures at Istituto Nazionale dei Tumori was provided).  
The fresh aseptic surgical sample was minced into fragments and incubated with 
collagenase (Sigma) for three hours, after which the cell suspension was filtered through a 
70 µM nylon mesh, treated with ACK (Ammonium-Chloride-Potassium) Lysing Buffer 
(Thermo Fisher), washed with RPMI medium supplemented with 0.5% BSA and seeded in 
a 100 x 200 mm tissue culture dish in DMEM/F-12 GlutaMAXTM media (Gibco) + 1% 
Penicillin-Streptamycin. Approximately 15 days after seeding, spheroid cellular aggregates 
could be isolated and propagated. Organoids were maintained as suspension culture in a 
humidified incubator at 37°C with a supply of 5% CO2.  
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Organoids culture was mainly composed of round-shaped cellular aggregates in which the 
cells exhibited adhesion loss and were organized in ring and/or ribbon-like structures. The 
corresponding tumour sample from which they were derived showed solid nests of poorly 
differentiated cells. Organoids showed a high expression of Ki-67 and the in situ 
hybridization (ISH) of Lgr5 marker showed that it was very focally expressed by some 
apical and peripheral cells. 
Moreover, the mutation pattern of organoids in formalin fixed paraffin embedded (FFPE) 
sections reflected that in the original tumour sample (Table 5).  
 
 
 
 
3.4 Trypan blue viability assay 
Organoids were disaggregated and seeded in triplicates into a 6 well plate (3-4 × 
105 cells per well). After 24 hours they were treated with 5 mM metformin for 120 hours 
or left untreated. Fresh medium added with metformin was replaced every 24 hours. Cells 
were pelleted and disaggregated by vigorous pipetting in trypsin for 5-10 minutes. 
Disaggregated cells were put on ice and 50 ul in triplicate were added with an equal 
volume of trypan blue and loaded on a burker chamber for counting. 
 
3.5 Bromodeoxyuridine (BrdU) proliferation assay 
CRC cells were seeded at a concentration of 1 × 104 directly on 13 mm diameter 
coverslips (ThermoFisher Scientific).  After 24 hours HT29, HCT116 and HCT116P53-/- 
cell lines were treated with 5 mM metformin and DLD-1 cells with 10 mM metformin, 
Table 5. Genetics characterization of the origin tumour and of the derived CRC-
pc organoids 
 LKB1 BRAF KRAS TP53 
Surgical sample N.D. V600E WT R273H 
CRC-pc organoids WT V600E WT R273H 
N.D. not detected     
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dissolved in medium or left untreated for 24, 48 or 72 hours. Cells were incubated with 33 
µM BrdU (Sigma Aldrich) dissolved in medium. After 2 hours coverslips were washed 
twice in 1X PBS and stored at 4oC. Cells were incubated 45 minutes with anti-BrdU 
primary antibody (BD Bioscience) diluted 1:5, and then they were treated 45 minutes with 
secondary antibody FITC-conjugated (Jackson Immuno Research) at 1:50 dilution. To 
visualize the nuclei, cells were treated with DAPI (4',6-diamidino-2-phenylindole; Sigma 
Aldrich) diluted 1:3000 in 1 X PBS. Images were acquired with an Olympus BX-61 
automated upright microscope (Shinjuku).  
 
3.6 Fluorescence-activated cell sorting (FACS) 
Cells were plated in 10 mm Petri dishes (2 x 105 cells/well) and after 24 hours 
treated with metformin or left untreated for 72 or 120 hours. Cells were harvested, and 
washed with 0.5% BSA and 2 mM EDTA and dissolved in PBS. Then, 5 x 105 cells were 
suspended in 50 µl of buffer containing 1 X PBS, 0.5% BSA and 2 mM EDTA followed 
by the addition of 1µl of fluorescent dye-conjugated monoclonal antibody CD133-PE or 
CD44-PE (Myltenyi Biotec). Cells were incubated for two hours in the dark at 4°C, 
washed and suspended in 200 µl of the buffer described above and analyzed using a 
FACSCanto II (Becton Dickinson).  
 
3.7 RNA extraction from cells 
Total RNA was extracted from cells using the Trizol reagent (Invitrogen). After 
adding 500 µl of this reagent and 100 µl of chloroform, the samples were left at RT for 5 
min. Subsequently, samples were centrifuged at 12000 rpm for 15 min at 4°C and the 
supernatant was transferred into a new tube where the same amount of isopropanol was 
added. After adding 5 µl of glycogen (5mg/mL, Ambion), the samples were left at RT for 
15 min and then centrifuged again at 12000 rpm for 15 min at 4°C. The supernatant was 
removed, 400 µl of ice cold 75% ethanol was added to the aqueous phase and the mixture 
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was centrifuged at 13200 rpm for 10 min at 4°C. After removing the supernatant, the pellet 
was dried and resuspended with RNAse-free water. 
 
3.8 Quantitative real-time PCR (qRT-PCR) 
TaqMan gene expression assays were used for qRT-PCR. Briefly, 500 ng of total 
RNA in a final volume of 20 µl were reverse transcribed to cDNA using High-Capacity 
cDNA Reverse Transcription Kit according to the manufacturer’s instructions 
(ThermoFisher). qRT-PCR was performed using the FAST chemistry (ThermoFisher) with 
the manufacturer provided gene-specific assay (CD44 Hs00153304_m1 and LGR5 
Hs00173664_m1) in ABI PRISM 7900 HT Real-Time PCR system (ThermoFisher). The 
expression levels of each assay were normalized to that of GAPDH (Hs99999905_m1). 
Data analysis was done using the Sequence Detector version, SDS 2.1. 
 
3.9 Cell Cycle analysis  
Cells were plated in 10 mm Petri dishes (5×105 cells/well) and after 24 hours 
treated with metformin, targeted drugs (alone or in combination with metformin) or left 
untreated for 72 or 120 hours. Cells were scraped, rinsed twice with 1 X PBS and fixed in 
ice-cold 70% ethanol. For total DNA content 106 cells were stained with a solution 
containing 50 µg/ml propidium iodide and 250 µg/ml RNase I (Roche Diagnostics) and left 
overnight at 4°C. Cell cycle distribution was evaluated by flow-cytometric analysis of 
cellular DNA content via FACS instrument (Beckton & Dickinson). 
 
3.10 Western Blotting analysis  
Logarithmically growing cells were treated with metformin or targeted drugs 
(alone or in combination with metformin) or left untreated for 72 or 120 hours. Then cells 
were washed twice with ice-cold PBS, collected by trypsinisation and resuspended in 300	
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μl of 1X SDS sample buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 0.5% Triton X-100, 0.1% 
sodium deoxycholate, 0.25% sodium dodecyl sulphate (SDS)) supplemented with protease 
inhibitors (Calbiochem), and phosphatase inhibitor cocktail (PhosSTOP Roche). The 
suspensions were then sonicated for 5 seconds (two cycles) to shear DNA and reduce 
viscosity. For each sample 40	 μg of protein lysate were precipitated using 100% cold 
acetone for 20 minutes at -20°C, then centrifuged at 8000 rpm for 7 minutes and dried in a 
speed vacuum for 10 minutes. Protein quantification was performed using the BCA protein 
assay (Thermo Scientific). The pellets were resuspended in 20	μl of 1X loading buffer (200 
mM Tris HCl pH 6.8, 8% SDS, 0.4% Bromophenol blue, 40% Glycerol) and then boiled at 
98°C for 5 minutes. Samples were loaded onto to 8-12% polyacrylamide gels.  Proteins 
were then transferred on Nitrocellulose membranes (Whatman PROTRAN) with porosity 
of 0.2 µm or 0.45 µm depending on the size of the protein being detected. Membranes 
were blocked with 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween-20 and 
incubated with primary antibodies. The primary antibodies used for Western blotting are 
showed in Table 6. Immmunoreactive proteins were visualized using chemiluminescence 
(SuperSignal West Dura Chemiluminescent Substrate, Thermo Scientific) and protein level 
quantification was performed using the software Imagelab©.  
Table 6. Antibodies used for immunoblotting analysis. 
Antigen Antibody Type Species Dilution Supplier 
phospho-Rb (Ser780) 
(C84F6) 
#3590 Monoclonal Rabbit 1:1000 Cell Signaling 
Cyclin D1 (H-295) sc-753 Polyclonal Rabbit 1:500 
Santa Cruz 
Biotechnology 
Cyclin E1 (HE12) #4129 Monoclonal Mouse 1:1000 Cell Signaling 
c-Myc (D84C12) #5605 Monoclonal Rabbit 1:1000 Cell Signaling 
cleaved-PARP (Asp214) 
(Human Specific) 
#9541 Polyclonal Rabbit 1:1000 Cell Signaling 
LC3B #2775 Polyclonal Rabbit 1:1000 Cell Signaling 
AMPKα #2793 Monoclonal Mouse 1:1000 Cell Signaling 
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phospho-AMPKα 
(Thr172) (40H9) 
 
#2535 Monoclonal Rabbit 1:1000 Cell Signaling 
S6 Ribosomal Protein 
(54D2) 
#2317 Monoclonal Mouse 1:1000 Cell Signaling 
Phospho-S6 Ribosomal 
Protein (Ser240/244) 
#2215 Polyclonal Rabbit 1:1000 Cell Signaling 
4E-BP1(53H11) #9644 Monoclonal Rabbit 1:1000 Cell Signaling 
phospho-4E-BP1 
(Thr37/46) 
#9455 Polyclonal Rabbit 1:1000 Cell Signaling 
mTOR #2972 Polyclonal Rabbit 1:1000 Cell Signaling 
phospho-mTOR 
(Ser2448) (D9C2) XP 
#5536 Monoclonal Rabbit 1:1000 Cell Signaling 
IGF-1 Receptor β #3027 Polyclonal Rabbit 1:1000 Cell Signaling 
phospho –IGF-1 Receptor 
β (Tyr1135/1136)/Insulin 
Receptor  
#3024 Monoclonal Rabbit 1:1000 Cell Signaling 
p44/42 MAPK (Erk1/2) #9102 Polyclonal Rabbit 1:1000 Cell Signaling 
Phospho-p44/42 MAPK 
(Erk1/2) Thr202/Tyr204) 
(20G11) 
#4376 Monoclonal Rabbit 1:1000 Cell Signaling 
Akt (pan) (40D4) #2920 Monoclonal Mouse 1:2000 Cell Signaling 
phospho-Akt (Ser473) 
(D9E) XP 
#4060 Monoclonal Rabbit 1:2000 Cell Signaling 
Src (36D10) #2109 Monoclonal Rabbit 1:1000 Cell Signaling 
phospho-Src Family 
(Tyr416) 
#2101 Polyclonal Rabbit 1:1000 Cell Signaling 
EGFR (1005) sc-03 Polyclonal Rabbit 1:1000 
Santa Cruz 
Biotechnology 
phospho-EGFR (Tyr1068) 
(D7A5) XP 
#3777 Monoclonal Rabbit 1:1000 Cell Signaling 
Vinculin V9131 Monoclonal Mouse 1:5000 
Sigma-
Aldrich 
β-actin A2066 Polyclonal Rabbit 1:5000 
Sigma-
Aldrich 
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3.11 Senescence-associated (SA)-β-galactosidase activity  
CRC cell lines were seeded in a 35 mm multi-well plate (3.75 – 30 × 104 
cells/well) and treated with 5 mM metformin dissolved in medium or left untreated.  After 
72 hours the SA-β-galactosidase activity was detected using the Senescence β-
galactosidase staining kit (Cell Signaling Technology) in accordance with the 
manufacturer's instructions. Cell images were acquired under reflected light using an 
Olympus IX81 motorized inverted microscope (Shinjuku).  Positive control for β-
galactosidase assay was obtained as described in Vizioli et al., 2014. 
 
3.12 Apoptosis assays 
For all the apoptosis assays the adherent cells were collected by trypsinization and 
then pooled together with the detached cells from the same sample. 
 
3.12.1 TUNEL (TdT-FITC)  
TUNEL assay was performed using the In Situ Cell Death Detection Kit 
Fluorescein (Roche) for detection of single and double stranded DNA breaks that occur at 
the late stages of apoptosis. Cells were seeded at concentration of 5 × 105 and, after 24 
hours, treated with metformin or left untreated for 72 hours. Cells were harvested, washed 
with 1X PBS, fixed in 1% formaldehyde for 20 minutes on ice. Subsequently, the cells 
were washed with buffer (1 X PBS, 1% BSA) and fixed in ice-cold 70% ethanol. Cells 
were washed with buffer and incubated with the TdT (Terminal deoxynucleotidyl 
Transferase) enzyme and label solution (fluorescein-dUTP) for 1 hour at 37oC. After 
washing with PBS containing 1% BSA, the label incorporated was visualized on a 
FACSCanto II (Becton Dickinson).  
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3.12.2 Caspase-3 assay 
Cells were seeded at the density of 5 × 105 cells and after 24 hours treated with 
metformin or left untreated for 72 hours. Cells were harvested, washed with 1 X PBS, 
fixed in 1% formaldehyde dissolved in 1 X PBS for 20 minutes on ice. Cells were washed 
with buffer and fixed in ice-cold 70% ethanol. After another washing cells were 
resuspended in 1 X PBS, 0.1% Triton X-100 and incubated for 10 minutes at RT. Cells 
were washed in buffer and resuspended in 1 X PBS, 10% normal goat serum for 30 
minutes. Cells were resuspended in 100 µl buffer containing antibody anti caspase-3 (Cell 
Signaling Technology) diluted 1:50 and incubated for 1 hour at RT. This was followed by 
a second staining with a rabbit anti FITC (fluorescein) polyclonal antibody (Cell Signaling 
Technology) diluted 1:50 and incubated for 1 hour at RT in the dark. Cells were analyzed 
on a FACSCanto II (Becton Dickinson). 
 
3.13 Western blot for apoptotic control  
Logarithmically growing HL-60 cells were treated with camptothecin (CPT) 0.1 
µM or left untreated for 8 hours. Protein extraction and immunoblot protocol were 
performed as preliminary reported. 
 
3.14 Immunofluorescent staining and image analysis for autophagy  
CRC cell lines were seeded at the density range of 2.5 – 10 × 104 cells directly on 
13 mm diameter coverslip. After 24 hours cells were treated with 5 mM metformin 
dissolved in medium or left untreated. After 72 hours cells were fixed in 4% 
paraformaldehyde, permeabilized with ice-cold 100% methanol and blocked with 1 X PBS, 
5% normal goat serum and 0.3% Triton X-100. After blocking, the coverslips with cells 
were incubated with anti-LC3B antibody, used 1:400 in dilution buffer (1 X PBS, 1% BSA, 
0.3% Triton X-100), overnight at 4°C in the dark. Coverslips were incubated with 
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secondary antibody for 2 hours in the dark at RT. To visualize the nuclei, cells were treated 
for 2 min with DAPI (4',6-diamidino-2-phenylindole) and diluted 1:3000 in 1 X PBS. 
Finally the coverslips were placed on a support in presence of mowiol mounting solution 
overnight at RT in the dark. Images were acquired with Olympus BX-61 automated 
upright microscope (Shinjuku).  
Hela cells were used as positive control for the autophagy assay. Cells were seeded at the 
density of 12.5 × 104 cells directly on 13 mm diameter coverslip (Fisher Scientific). After 
24 hours cells were treated for 24 hours with 50 µM chloroquine dissolved in medium or 
left untreated. 
 
3.15 Clonogenic Assay 
CRC cells were seeded in 35 mm multi-well plates (102 cells/well) and treated 
with 5 mM metformin dissolved in medium or left untreated for 6, 12 and 18 days. Every 3 
days medium was refreshed. To verify their ability to restart their growth after prolonged 
treatments with metformin, cells were treated with metformin for 6, 12 and 18 days and 
allowed to grow for 6, 12 and 18 days respectively in fresh medium in absence of the drug. 
At the end of treatments, the wells were rinsed with PBS and stained with Crystal Violet 
(Sigma Aldrich) for 2 min. Only the clearly visible colonies were counted under the 
microscope.  
 
3.16 Viability assays in combinatorial treatments: chemotherapy drugs 
and metformin 
To assess the effects of chemotherapy drugs in combination with metformin, 
MTT viability assays were performed as previously described. The drugs were tested alone 
or combined in different settings. For each drug the concentration administered was its 
IC50; metformin was used at the concentration of 5 mM. The cells were exposed to 
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individual drugs alone or to their combined treatment for 96 hours or in different 
sequences, metformin at first or vice versa (where metformin and the chemotherapy drugs 
were given for 72 and 24 hours, respectively). Cells were also exposed to longer treatments 
where chemotherapy drugs were administered for 3 days and then the medium was 
replaced with metformin for 3 more days and vice versa (at first metformin and then 
chemotherapy drugs). For each treatment the medium was refreshed every 48 hours.  
The experimental design showing the different sequences of the treatments administered is 
summarised in Figure 8. 
 
Figure 8. Experimental design of the treatments with metformin and chemotherapy 
drugs. The cells were left untreated (CTRL, white arrows) or treated with metformin 
(MET, black arrows) and chemotherapy drugs, 5-FU, Oxaliplatin and irinotecan - 
(CHEMO, grey arrows), given alone or administered simultaneously (CHEMO-MET, 
grey/black arrows) for 96 hours. The cells were also exposed to drugs in different 
sequences: metformin at first or vice versa; where metformin was always administered for 
72 hours (replaced in fresh medium after 48 hours) and the chemotherapy drugs were 
given for 24 (METàCHEMO or CHEMOàMET) or 72 hours (METàCHEMO3 or 
CHEMO3àMET). In CTRL, MET, CHEMO and CHEMO-MET treatments fresh medium 
(with or without drugs) was replaced every 48 hours. In CHEMOàMET treatment the 
medium with chemotherapeutics drugs was added for 24 hours and then replaced for 72 
hours with medium containing metformin (fresh medium with metformin was added after 
48 hours); in METàCHEMO treatment the cells were treated with metformin for 72 hours 
(fresh medium with metformin was added after 48 hours) and then for 24 hours with new 
medium containig chemotherapeutic drugs. In CHEMO3àMET treatment the cells were 
treated with chemotherapeutic drugs for three days (chemotherapeutics drugs were added 
at the beginning of treatment and after 48 hours) then for 72 hours with metformin 
(replaced after 48 hours); in METàCHEMO3 treatment the cells were treated with 
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metformin for 72 hours (metformin was added at the beginning of treatment and replaced 
after 48 hours), then for 72 hours with chemotherapeutic drugs (replaced after 48 hours). 
Because in CHEMOàMET and METàCHEMO treatments the chemotherapeutic drugs 
were administered once, while in the other treatments they were administered twice, a 
treatment with chemotherapeutic drugs administered for 24 hours would be added as 
control.  
 
 
 
 
3.17 Drug synergy testing  
Analyses for the detection of drug interactions among chemotherapy drugs (5-FU 
and oxaliplatin and 5-FU and irinotecan) or among metformin and targeted drugs were 
performed. Starting from the IC50 value of the drugs previously obtained, I conducted MTT 
viability assays at 72 hours with combination of multiples and submultiples for each IC50: 
from 6.25% to 2 times of the IC50.  
Effects of the drug interactions were analysed using the CompuSyn software (Compusyn 
Inc), which determines the dose-effect of each drug. This software is based on Chou and 
Talalay method (Chou and Talalay, 1984) and can determine synergism and antagonism 
between drugs through the combination index (CI) theorem: CI =1 is considered additive 
effect, CI<1 synergism and CI>1 antagonism. 
 
 
3.18 Viability assays in combinatorial treatments: chemotherapy 
regimens and metformin 
To assess the effect of chemotherapy regimens in combination with metformin, 
MTT viability assays were performed as previously described. The drugs were tested alone 
or combined in different sequences as previously described, as reported in Figure 9. The 
concentrations of regimens used in the experiments were determined using the Compusyn 
software; metformin was used at the concentration of 5 mM. 
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Figure 9. Experimental design of the combined treatments of metformin with the 
chemotherapy regimens. The cells were left untreated (CTRL, white arrows) or treated 
with metformin (MET, black arrows) and chemotherapy regimens (REGIMEN, grey 
arrows) given alone or administered simultanoeulsy (REGIMEN-MET, grey/black arrows) 
for 96 hours. The cells were also exposed to drugs in different sequences: metformin at 
first or vice versa; where metformin was always administered for 72 hours (replaced in 
fresh medium after 48 hours) and the chemotherapy regimen were given for 24 
(METàREGIMEN or REGIMENàMET) or 72 hours (METàREGIMEN3 or 
REGIMEN3àMET). The regimens investigated are: oxaliplatinum-5-FU (OXA-5-FU) 
and irinotecan-5-FU (IRI-5-FU). For each condition medium was replaced every 48 hours: 
In CTRL, MET, REGIMEN and REGIMEN -MET treatments fresh (with or without 
drugs) was replaced every 48 hours. In REGIMENàMET treatment the medium with 
chemotherapeutics drugs was added for 24 hours and then replaced for 72 hours with 
medium containing metformin (fresh medium with metformin was added after 48 hours); 
in METà REGIMEN treatment the cells were treated with metformin for 72 hours (fresh 
medium with metformin was added after 48 hours) and then for 24 hours with new 
medium containig chemotherapeutic drugs. In CHEMO3àMET treatment the cells were 
treated with chemotherapeutic drugs for three days (drugs were added at the beginning of 
treatment and after 48 hours) then for 72 hours with metformin (replaced after 48 hours); 
in METà REGIMEN3 treatment the cells were treated with metformin for 72 hours 
(metformin was added at the beginning of treatment and replaced after 48 hours), then for 
72 hours with chemotherapeutic drugs (replaced after 48 hours). Because in 
REGIMENàMET and METàREGIMEN treatments the chemotherapeutic drugs were 
administered once, while in the other treatments they were administered twice, a treatment 
with chemotherapeutic drugs administered for 24 hours would be added as control.  
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3.19 Data analyses 
Data analyses were done using the GraphPad Prism software. The data are 
presented as mean values ± standard deviation (SD) and statistically compared between 
groups using one-way analysis of variance followed by Student’s t-test. A P-value of <0.05 
was considered statistically significant. 
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CHAPTER 4 
RESULTS 
 
4.1 Effect of metformin on CRC cell lines and organoids 
4.1.1 Identification of the concentrations of metformin to use in CRC cell lines and 
organoids  
To determine the best concentrations of metformin to use in the treatments, MTT 
(3-4,5-Dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) viability assays were 
performed on four CRC cell lines: HT29, HCT116 HCT116P53-/- and DLD-1. As shown 
in Figure 10, the half inhibitory concentration (IC50) after 72 hours of treatment with 
metformin was about 2.5 mM for HT29, HCT116 and HCT116P53-/- cells and 5 mM for 
the DLD-1 cell line. However, other experiments conducted on these cell lines in our 
laboratory and previously published data in CRC (Zakikhani et al., 2008) treated HT29, 
HCT116 and HCT116P53-/- cells with 5 mM metformin and the most resistant DLD-1 cell 
line with 10 mM metformin. To be in line with these data, we decided to treat cells as in 
Zakikhani (Zakikhani et al., 2008). 
 
Figure 10. Determination of the IC50 values for metformin in CRC cell lines. HT29, 
HCT116, HCT116P53-/- and DLD-1 cell lines were seeded in six replicates in a 96-well 
plate and treated with metformin at different concentrations (from 0.16 to 20 mM). After 
72 hours of treatment MTT assay was used to determine the percentage of viable cells. 
Results are representative of three independent experiments. 
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In the clinics, metformin is typically administered at doses of 0.5-1g/day, and its median 
plasma concentration is 330 µM (Foretz et al., 2014). In vitro inhibition of cancer cell 
proliferation, however, has been reported for millimolar concentrations (Lonardo et al., 
2013) and the concentration used in our and other CRC in vitro studies is therefore higher 
than the therapeutic one. However, metformin accumulates in tissues at concentrations that 
are several times those found in blood (Foretz et al., 2014), and drug concentrations in the 
gut are higher than in the rest of the body (Pernicova et al., 2014). In addition CRC cells 
express high levels of the main metformin transporter OCT1, which may increase their 
uptake of metformin (Zhang et al., 2006). These observations may justify testing the use of 
higher metformin concentrations to treat CRC. MTT viability assay was not applicable to 
3D-organoids derived from a CRC mestastasis to the peritoneum (peritoneal 
carcinomatosis CRC-pc), because the 3D structure of organoids renders difficult to 
metabolize MTT. As shown in Figure 11 A, the best concentration to use for their 
treatment (5 mM) was determined by giving to organoids increasing concentrations of 
metformin (from 1 to 20 mM) and following their growth over time, until they were 
disaggregated (120 hours). Trypan Blue assay confirmed a reduction in cell viability when 
organoids were treated with 5mM metformin for 120 hours (Figure 11 B). 
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Figure 11. Microscope images and viability analysis of organoids from CRC-pc. (A) 
Micrographs of organoids before and after metformin treatment for 120 hours at different 
drug concentrations. Metformin treatments induced a marked morphological change in 
organoids, resulting in a loss of their original spheroid organization. Magnifications: 10X. 
Scale bars = 50 µm. (B) Organoids were treated with 5 mM metformin for 120 hours. The 
percentage of cell death was determined by Trypan Blue assay. Data are measured 
percentage of cell death and expressed as the mean ± SD.  
 
 
4.1.2 Analysis of cell proliferation in CRC cell lines undergoing metformin treatment  
A BrdU incorporation assay confirmed that 5 mM metformin inhibited growth in 
HT29, HCT116 and HCT116P53-/- cells after 24 hours of treatment, but the effect became 
more significant after 72 hours (from 54% to 23% in HT29, from 78% to 44% in HCT116 
and from 50% to 26% in HCT116P53-/- cells; Figure 12 A, B, C). In DLD-1 cells a slight 
reduction in proliferation was observed after 24 hours of treatment (from 61% to 52%), but 
not after 48 and 72 hours (from 57% to 54% and from 46% to 43% respectively; Figure 12 
D).  
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Figure 12. Evaluation of the proliferation in CRC cell lines. Cell proliferation in HT29 
(A), HCT116 (B), HCT116P53-/- (C) and DLD-1 (D) cell lines was evaluated in vitro by 
means of BrdU incorporation in absence (Ctrl) or presence of 5 mM for HT29, HCT116 
and HCT116P53-/- or 10 mM metformin for DLD-1 after 24, 48 and 72 hours of 
treatment. Metformin inhibits proliferation in HT29, HCT116 and HCT116P53-/- cell lines 
at all time points. In DLD-1 cells the reduction is observed only after 24 hours of 
treatment. Results, derived from three independent experiments, are represented as the 
mean ± SD compared with the untreated control group (*P < 0.05, **P < 0.01, ****P < 
0.0001). 
 
 
4.1.3 Evaluation of stem cell markers in CRC cell lines and organoids  
The expression of the CRC stem cell markers CD44, CD133 and of Lgr5 was 
evaluated on the four CRC cell lines and on the organoids. As shown in Figure 13, 
treatment with metformin significantly decreased the expression of CD133 (not expressed 
in HCT116P53 -/- cells), CD44 and Lgr55 (which was expressed only in HT29 cells (Chen 
et al., 2014) and in the organoids). 
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Figure 13. Effects of metformin on the expression of the CRC stemness markers 
CD44, CD133 and Lgr5.  FACS and qRT-PCR analyses on (A) Cell lines and (B) 
organoids. A representative FACS analysis showing changes in the proportion of CD133+ 
cells and organoids and CD44+ organoids induced by metformin.  qRT-PCR results of the 
expression of CD44+ in cell lines and Lgr5 in cell lines and in the organoids. Data are 
indicated as 2-∆Ct (delta cycle threshold), which is directly related to the gene expression 
levels in each sample, and represent mean ±SD from three different replicates.  
 
 
4.1.4 Metformin increases G0/G1 phase in HT29, HCT116, HCT116P53-/- and 
organoids but not in DLD-1 cells 
To study the cellular mechanisms that reduce proliferation regulated by 
metformin, I evaluated changes in the cell cycle progression. After 72 hours, for cell lines, 
or 120 hours, for organoids, of treatment, the distribution of cells in the cell-cycle phases 
was determined by analyzing their DNA content by FACS. The DNA profiles of HT29, 
HCT116 WT and TP53-null cells and of CRC-pc organoids treated with metformin 
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compared to that of untreated cells (or organoids) showed a slight accumulation of cells in 
G0/G1 phase (from 50% to 63% in HT29, from 49% to 64% in HCT116, from 36% to 
46% in HCT116P53-/- cells and from 56% to 70% in the organoids; Figure 14 A). A 
corresponding decrease in the percentage of the G2/M phase fraction (from 7% to 5.5% in 
HT29, from 16% to 13% in HCT116 and from 29% to 22% in HCT116P53-/- cells) 
respect to the untreated cells was observed. Organoids treated with metformin showed a 
decrease of cells in S phase (from 31% to 17%), while DLD-1 cells had no changes in the 
cell cycle.  
To confirm that metformin treatment induced an increase of cells in the G0/G1 phase I 
evaluated the expression of two cyclins, cyclin D1 and cyclin E, which are involved in the 
progression through G1 phase (cyclin D1) and the transition from G1 to S phase (cyclin E). 
Decrease in their levels could be associated with cell cycle arrest. Western blot analysis 
showed that cyclin D1 (expressed at low levels in HT29 cells) was downregulated in all the 
cell lines tested, included DLD-1 cells, and even in CRC-pc organoids, which support the 
cell cycle arrest in the G0/G1 phase observed (Figure 14 B). In line with the inactivation of 
cyclin D1, metformin decreased the phosphorylation of its downstream target 
retinoblastoma protein (pRb; Ser780) in all the cell lines; the organoids did not express this 
protein. Cyclin E (not expressed in the organoids) had no change of expression in HT29, 
HCT116 and HCT116P53-/- but decreased in DLD-1 cells (Figure 14 B). The strong 
reduction of the expression of c-Myc confirmed the decrease of cells in S phase.  
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Figure 14. Cell cycle analysis and expression of related protein in CRC cell lines and 
in organoids.  (A) Proliferating colorectal cancer cell lines and CRC-pc were treated with 
metformin, Met, (+) or left untreated (-) for 72 hours (cell lines) or 120 hours (organoids). 
The cell cycle profiles were analysed by flow cytometry; an increase in G0/G1 fraction 
was observed in HT29, HCT116 WT and TP53-null cells and in the organoids. (B) 
Immunoblotting of pRb, cyclin D1, cyclin E and c-Myc in the CRC cell lines and in 
organoids treated with metformin (+) or left untreated (-) at the same times reported above. 
Cyclin D1, pRb and c-Myc, when expressed, are downregulated in all the cell lines, cyclin 
E decreased only in DLD-1 cell line. β-actin was used as loading control. The presented 
data derive from one of the three independent experiments performed. 
 
 
4.1.5 Treatment with metformin does not induce senescence, apoptosis or autophagy 
To investigate the biological mechanisms by which metformin appears to inhibit 
cell cycle progression, I assessed its ability to induce a permanent cell cycle arrest 
(senescence) or trigger cell death programs (apoptosis or autophagy) in the four cell lines. 
As regards the organoids, which grow as 3D structures, I could only evaluate protein 
changes by western blotting since most the assays I used are designed for disaggregated 
 	 57 
cells that grow as monolayer. Cellular senescence is an irreversible form of cell cycle 
arrest in which cells change their morphology, become flat and display a pH-dependent β-
galactosidase activity. Using a commercial system that detects the β-galactosidase activity 
of senescent cells, I observed no changes in morphology and β-galactosidase staining of 
cells after treatment with metformin in all of the tested cell lines, thus excluding activation 
of senescence (Figure 15).  
 
Figure 15. Analysis of senescence in CRC cell lines. Senescence was measured using the 
senescence-associated β-galactosidase (SA-β-Gal) activity assay. The cells were treated 
with metformin (+) or left untreated (-) for 72 hours. The images were acquired at 20x 
magnification. As shown in the images, no induction of senescence was reported in all cell 
lines. The positive control for the experiment is shown on the bottom panel: human 
primary thyrocytes carrying ER:RAS vector were left untreated (-) or treated (+) with 200 
nM 4-hydroxytamoxifen (4-OHT) for 7 days (magnification 40x). Data are from a 
representative experiment out of the three done independently.  
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Apoptosis, a programmed mechanism of cellular self-killing, was evaluated by FACS 
analysis for Caspase-3 and TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick 
End Labeling) assay, two different methods that detect the early and the late phases of 
apoptosis, respectively. Both assays showed no induction of apoptosis after 72 hours of 
treatment for all the tested cell lines (Figure 16 A-B). The absence of apoptosis was also 
confirmed by the lack of increase in cleavage of Poly (ADP-Ribose) polymerase protein 
(PARP; Asp214), a marker for late-stage apoptotic events, both in cell lines and in the 
organoids (Figure 16 C). 
 
 
 
Figure 16. Apoptosis assays in CRC cell lines and in the organoids. (A) Flow 
cytometric detection of cells containing active caspase-3, (B) TUNEL analysis on the cell 
lines and (C) protein detection of cleaved-PARP of the cell lines and of organoids treated 
with metformin (+) or left untreated (-) for 72 hours (cell lines) or 120 hours (organoids). 
The HL-60 cell line (bottom panel) was used as positive control: cells were treated with 
camptothecin (CPT +) or left untreated (-) for 8 hours. No apoptosis was reported in all the 
experiments. β-actin was used as loading controls. Results are representative of three 
independent experiments. 
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As regards autophagy, I monitored the conversion of the autophagy marker microtubule-
associated protein light chain 3 (LC3) from LC3-I to LC3-II, which is related to the 
presence of autophagosomes, double-membrane vesicles assembled during autophagy. 
Western blotting analysis of the ratio between LC3-I and LC3-II, as well as 
immunofluorescence for LC3B, were not significantly different after treatment with 
metformin, thus excluding the induction of autophagy in all cell lines and also in CRC-pc 
organoids (Figure 17).  
 
 
 
Figure 17. Autophagy detection in CRC cell lines and in the organoids. (A) 
Immunofluorescence staining of LC3B in the cell lines treated with metformin (+) or left 
untreated (-) for 72 hours (magnification 20x). The positive control is in the panel on the 
right: Hela cells treated with 50 mM chloroquine (+) or left untreated (-) for 24 hours 
(magnification 40x). (B) Immunoblotting determination of LC3B protein in the cell lines 
and in the organoids treated with metformin (+) or left untreated (-) for 72 or 120 hours. β-
actin was used as loading control. No autophagy was detected in both the experiments. The 
presented data derives from one of the three independent experiments performed. 
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4.1.6 Metformin-induced inhibition of proliferation is reversible  
To clarify the absence of induction of cell death after administration of metformin I 
examined the clonogenic capacity of the cell lines in the presence of the biguanide. 
Clonogenic cell survival assay defines the ability of a single cell to proliferate and form a 
large colony. I evaluated as metformin can stop the proliferation of CRC cells and also if 
the cells previously treated with metformin and then maintained on growth without the 
drug (here and after named “rescued cells”, R), are able to restore their proliferation 
capacity in each time of treatment. Treatment for 6 days with metformin significantly 
reduced both the number and size of colonies compared to the untreated controls in HT29, 
HCT116 and HCT116P53-/- (Figure 18 A). This result was confirmed after 12 days and 
was maintained up to 18 days of treatment (Figure 18 B-C). At this last time, colonies of 
untreated and rescued cells were larger and thicker than the other times. The confluence of 
the cells on these plates caused a massive detachment of the colonies during the treatment 
with crystal violet.  
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Figure 18. Clonogenic ability of the CRC cell lines. The cells were grown for 6 (A), 12 
(B) and 18 (C) days in the presence (Met, or +) or absence (Ctrl, or-) of metformin. The 
rescued colonies (R) were obtained after growth of cells treated with metformin for 6, 12 
or 18 days for further 6, 12 or 18 days respecitively in fresh complete medium without 
metformin. The graphic representation of the results is shown on the right side of the 
figure. Metformin reversibly inhibits colony formation of all the cell lines analysed. The 
bars indicate the mean value ± SD of three independent experiments (*P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001). 
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At all time points of treatment rescued cells resumed their proliferation capacity, although 
the recovery was less evident in HCT116 TP53-null cells. This effect does not seem to 
depend on TTP53 status, which is also mutated in HT29 cells. These results are in 
agreement with the absence of cell death observed, and highlight that the inhibitory effect 
of metformin on proliferation of HT29, HCT116 WT and TP53-null cells is transient, and 
may be overcome after the removal of the drug.   
In accordance with the absence of cell cycle arrest observed in the DLD-1 cells, 
differences in the ability of forming colonies did not occur in DLD-1 cells at the three time 
points analysed. 
Although MTT assay demonstrated that the concentration of metformin I used for DLD-1 
cells (i.e. 10 mM) was sufficient to stop the growth of 50% of the cells, the results I 
obtained by testing different mechanisms known as modulated by metformin are 
controversial and do not fully support an effect of the biguanide on DLD-1 cells, at least at 
the concentration used. In fact, the DLD-1 cells had a slight decrease in proliferation 
(BrdU assay) only after 24 hours of treatment with metformin and did not show cell cycle 
arrest, despite the decrease of c-Myc and cyclins D1 and E. 
Most likely the hypermethylation of both alleles of the LKB1 gene, which plays a critical 
role in activating AMPK, limits the effects of metformin on these cells and makes more 
difficult understanding the mechanisms modulated by metformin in CRC. This is why I 
decided to study in details only the other three models of CRC, which all carry a functional 
LKB1 gene. 
 
4.1.7 Metformin transiently inhibits mTOR proliferation pathway and reduces the 
activation of IGF1R  
To investigate the molecular mechanisms by which metformin may inhibit the 
proliferation of CRC cells, I assessed by western blotting analysis changes of activation of 
the Insulin-like growth factor 1 β (IGF1Rβ) protein and of proteins from the 
 	 63 
AMPK/mTOR pathway on HT29, HCT116 and HCT116P53-/- cells and on the organoids. 
The inhibition of phosphorylation of mTOR (Serine2448) and of its downstream targets S6 
(Ser 240/244) and 4E-BP1 (Thr 37/46) was observed in all cell lines tested after treatment 
with metformin (Figure 19).  
 
 
Figure 19. mTOR pathway and IGF1Rβ  in CRC cell lines and in the organoids.  
Cell lines and CRC-pc organoids were treated with metformin (+) or left untreated (-) for 
72 hours (cell lines) or 120 hours (CRC-pc organoids). The “rescued” cells (R) were grown 
for 72 hours (cell lines) or 120 hours (CRC-pc organoids) with metformin and for a further 
72 or 120 hours in fresh complete medium without the drug. Metformin reversibly inhibits 
the activity of proteins from the mTOR pathway and of IGF1Rβ. β-actin and vinculin were 
used as loading controls. The results are representative of at least three independent 
experiments. 
 
However AMPK resulted phosphorylated (Thr172) only in the HT29 cell line and in the 
organoids, suggesting the presence of alternative mechanisms for the inactivation of this 
pathway in both HCT116 cell lines. After treatment with metformin, I also observed 
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reduction of IGF1Rβ protein phosphorylation (Tyr1135/36) in the three cell lines analysed, 
suggesting a reduced activity of the receptor. Expression of IGF1Rβ was very weak in 
organoids and its phosphorylation did not change after the addition of metformin. 
In all cases the phosphorylation profile of the rescued cells was similar to that of the 
untreated cells confirming what was observed in the colony formation assays and 
supporting the hypothesis that the inhibitory effect of the drug on cell proliferation is only 
transient. 	
4.1.8 Summary of key findings  
Treatment with metformin: 
• reduces cell proliferation and induces block in G0/G1 phase 
• acts on the cancer stem cell component 
• induces a transient and reversible block of cell proliferation 
• transiently inhibits the mTOR pathway and IGF1R activation 
 
4.2 Effects of metformin in combination with chemotherapy  
The experiments with metformin on the cell lines and on the organoids highlight 
its cytostatic effect on CRC, and set the bases for testing the biguanide together with other 
drugs, to identify possible cytotoxic combinations. To this aim I have explored the effects 
of metformin in combination with the standard chemotherapy drugs used for CRC 
treatment, (5-FU), oxaliplatin (OXA) and irinotecan (IRI), which interfere with DNA 
synthesis. The effects of these drugs are different: 5-FU blocks thymidine synthesis and 
stops DNA replication; OXA forms cross links in DNA, preventing DNA replication and 
transcription, and IRI inhibits the topoisomerase I, leading to block of both DNA 
replication and transcription. In our hypothesis their combination with metformin could 
enhance the effects of chemotherapy and result in increased cell death.  
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We focused on the CRC cell lines, for which there are data in the literature on the 
sensitivity or resistance to standard chemotherapy, and also because organoids are difficult 
to treat with the compounds commonly used for viability assays (for example MTT).  
In the literature there are several reports on the IC50 for 5-FU, OXA and IRI for the three 
CRC cell lines that I am using, even though they give different concentrations. This is 
because different protocols to determine cell viability (e.g. sulphorhodamine B assay, 
CellTiter 96 Non-Radioactive Cell Proliferation Assay and MTT) as well as various times 
of exposure to drugs (e.g. 1, 24 or 72 hours) have been used. Several IC50s have been 
proposed for 5-FU (4.2 µM, 5.2 µM, 8.2 µM, 20 µM and 112 µM), OXA (0.33 µM, 9 µM, 
24 µM) and IRI (1 µM, 7.8 µM, 13.8 µM, 550 µM) in HT29 cells. The published IC50 
concentrations of chemotherapy drugs in HCT116 were 0.7 µM and 4.3 µM for 5-FU, 0.3 
µM, 2.2 µM and 38 µM for OXA, 2.2 µM and 3.2 µM for IRI; in HCT116P53-/- the 
identified IC50 were 19.7 µM for 5-FU, 1.7 µM for OXA and 3.1 µM for IRI (Barone et al., 
2007, Boyer et al., 2004, Flis et al., 2009, Guichard et al., 2001, Guichard et al., 1998, 
Mans et al., 1999, Mariadason et al., 2003, Nannizzi et al., 2010). Starting from data from 
the literature, I determined for each cell line the IC50 value after 72 hours of treatment with 
various concentrations of the drugs using an MTT viability assay. I established a range of 
concentrations for each drug (8 points/treatment) that was applicable to all the cell lines: 
from 0.3 µM to 64 µM for 5-FU, from 0.064 µM to 8 µM for OXA and from 0.004 µM to 
4 µM for IRI. The viability plots and the IC50 identified are shown in Figure 20 and Table 
7 respectively. The IC50 values obtained have been used for the further experiments, also in 
combination with metformin which was used at the concentration of 5 mM.   
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Figure 20. Determination of the IC50 values for the chemotherapy drugs in CRC cell 
lines. HT29, HCT116 and HCT116P53-/- cell lines were seeded in six replicates in a 96-
well plate and treated with chemotherapy drugs at different concentrations: 0.3 - 64 µM for 
5-Fluoro Uracil (5-FU), 0.064 - 8 µM for oxaliplatin (OXA) and 0.004 - 4 µM for 
irinotecan (IRI). After 72 hours MTT assay was used to determine the cell viability. Table 
4 summarizes the IC50 values of the drugs obtained for each cell line. Results are 
representative of two independent experiments.  
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Table 7. IC50 values of chemotherapy drugs in 
the CRC cell lines analysed 
 HT29 HCT116 HCT116P53-/- 
5-FU 10 µM 6.8 µM 7.2 µM 
OXA 0.9 µM 0.77 µM 3.2 µM 
IRI 0.2 µM 0.024 µM 0.130 µM 
 
4.2.1 Analysis of combinatorial treatments with metformin and single 
chemotherapeutic drugs 
Because of the various time-serial combinations of metformin with 
chemotherapeutic drugs we had to analyse, we decided to use a comparison of cell viability 
(i.e. a cell viability assay) than the analysis with the combination index method. To assess 
whether combined treatments with metformin and chemotherapy drugs were more 
effective than individual treatments to induce a decrease in cell viability, the IC50 
concentrations selected for 5-FU, OXA, IRI and metformin were tested alone or combined 
in different settings: chemotherapy and metformin administered simultaneously (for 96 
hours) or in different sequences, metformin at first or vice versa (where metformin and the 
drugs were given for 72 and 24 hours, respectively). I also exposed the cells to longer 
treatments with the administration of chemotherapy drugs for 3 days and then the 
replacement of the medium with metformin for three more days and vice versa (at first 
metformin and then chemotherapy drugs). The experimental design showing the different 
sequences of administered treatments is summarised in Figure 8 of the Material and 
Methods chapter.  
 
4.2.1.1 Analysis of combinatorial treatments with metformin and 5-FU 
As shown in Figure 21 A, metformin (MET) and 5-FU given alone reduced cell 
viability in HT29 cells, and the effect was greater for 5-FU (MET vs 5FU, P value < 
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0.0001). The addition of MET to 5-FU (5FU-MET) had almost the same effect of the 
treatment with 5FU alone, in terms of cell viability. On the contrary, the administration of 
5-FU both for short (1 day) or longer (3 days) times before MET (5FUàMET and 
5FU3àMET) increased cell viability (5FU vs 5FUàMET, P value < 0.0001; 5FU vs 
5FU3àMET, P value = 0.0005), which is suggestive of an inhibitory effect of MET on 5-
FU. The administration of MET before 5-FU, both for short (1 day) or longer (3 days) 
times (METà5FU and METà5FU3), had no effects on the viability of the cells, which 
was similar to that observed in the untreated control.  
In the two HCT116 cell lines (TP53-WT and TP53-null) MET was more effective than 5-
FU in reducing cell viability (MET vs 5FU in HCT116, P value = 0.0385; in HCT116P53-
/- cells, P value < 0.0001), both when given alone and in combination with chemotherapy 
and the effect was stronger for the TP53-null cells (5FU vs 5FU-MET, in HCT116 P value 
= 0.0003; in HCT116P53-/- cells, P value < 0.0001; Figure 21 B and C). Sequential 
treatment given for a short time (5FUàMET and METà5FU) had more efficacy than 
treatments at longer times (5FUàMET vs 5FU3àMET in HCT116, P value < 0.0001, in 
HCT116P53-/-, P value = 0.0002) and the strongest effect was achieved when MET was 
administered before 5-FU (5FUàMET vs METà5FU in HCT116, P value < 0.0001; in 
HCT116P53-/- cells, P value = 0.0084). In HCT116 cells the longer exposure to 5-FU, 
both before and after MET (5FU3àMET and METà5FU3), had the lowest effect on the 
reduction of cell viability, while in HCT116P53-/- cells treatments for longer times had the 
same effects of 5-FU alone. 
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Figure 21. Effects of 5-FU and metformin treatments on CRC cell viability. The cells 
were seeded in six replicates in a 96-well plate and treated with metformin and/or 5-FU at 
their respective IC50 values. The cell proliferation rate was measured using the MTT assay. 
The bars indicate the mean value ± SD of three independent experiments (*P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001). O.D.= optical density. 
 
In summary, metformin has little effect on the viability of HT29 cells and, when given 
before 5-FU, it diminishes the efficacy of the chemotherapy. On the contrary, the 
biguanide strongly reduces the viability of the two HCT116 cell lines; however, its 
combination with 5-FU does not enhance the reduction of cell viability.   
 
4.2.1.2 Analysis of combinatorial treatments with metformin and oxaliplatin 
Similarly to what was observed for the treatment with 5-FU, MET and OXA 
given alone reduced viability in HT29 cells, and the effect was stronger for OXA (MET vs 
OXA, P value < 0.0001), while addition of MET to OXA (OXA-MET) gave similar results 
as treatment with OXA alone (Figure 22 A). Sequential treatments were less effective and 
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the administration of OXA before MET both for short and longer times (OXAàMET and 
OXA3àMET) reduced the viability of cells better than the opposite sequences of the 
drugs (METàOXA and METàOXA3; OXAàMET vs METàOXA and  OXA3àMET 
vs METàOXA3, P value < 0.0001). 
In the two HCT116 cell lines the administration of MET and OXA as single drugs 
markedly reduced the cell viability (Figure 22 B-C) and OXA-MET combination was even 
more effective (OXA vs OXA-MET in HCT116, P value < 0.0001; in HCT116P53-/- 
cells, P value = 0.0472). In HCT116 cells the synergistic effect of the two drugs was 
confirmed when OXA was administered sequentially with MET and for short times 
(OXAàMET and METàOXA; OXA vs OXAàMET, P value = 0.0078; OXA vs 
METàOXA, P value = 0.0103; Figure 20 B). Longer exposure to OXA (OXA3àMET 
and METàOXA3) was the treatment less effective. These results were not confirmed in 
the HCT116 TP53-null cells where OXAàMET, METàOXA and OXA3àMET 
treatments gave similar results to single treatment with MET, and the sequence 
METàOXA3 had the lowest reduction of cell viability.   
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Figure 22. Effects of oxaliplatin and metformin treatments on cell viability. The cells 
were seeded in six replicates in a 96-well plate and treated with metformin and/or 
oxaliplatin (OXA) at their respective IC50 values. The cell proliferation rate was measured 
using the MTT assay. The bars indicate the mean value ± SD of three independent 
experiments (*P < 0.05, **P < 0.01, ****P < 0.0001). 
 
These results confirm the poor efficacy of metformin on HT29 cells and its inhibitory 
effect on the chemotherapy. Metformin is more effective on the two HCT116 cell lines and 
shows a synergistic effect when combined with OXA.  
 
4.2.1.3 Analysis of combinatorial treatments with metformin and irinotecan 
All cell lines showed the same pattern of response to treatment with IRI and MET 
(Figure 23 A-B-C). IRI alone strongly reduced cell viability, and addition of MET 
diminished its effectiveness (IRI vs IRI-MET in HT29 cells, P value < 0.0001, in HCT116 
cells, P value = 0.0267, in HCT116P53-/- cells, P value < 0.0001). This was particularly 
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evident for the sequential treatments in which MET was added before IRI (METàIRI and 
METàIRI3), where I observed the highest cell viability, which was almost similar to that 
obtained for MET in single treatment. On the contrary, treatment with IRI for 3 days, 
followed by MET was the most effective (IRI vs IRI3àMET in HT29 cells, P value = 
0.0060, in HCT116 cells, P value < 0.0001, in HCT116P53-/- cells, P value = 0.0154). 
These data suggest that metformin could act as antagonist for IRI.  
 
Figure 23. Effect of irinotecan (SN-38) and metformin treatments on cell viability. 
The cells were seeded in six replicates in a 96-well plate and treated with metformin and/or 
irinotecan (IRI) at their respective IC50 values. The cell proliferation rate was measured 
using MTT assay. The bars indicate the mean value ± SD of three independent experiments 
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). 
 
 
4.2.2 Analysis of combinatorial treatments with metformin and chemotherapeutic 
drugs administered as regimens  
After having determined the effects of metformin in combination with 
chemotherapy drugs used for the treatment of CRC, I evaluated the effects of the biguanide 
in combination with standard chemotherapy regimens used for the first-line treatment of 
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CRC. These regimes combine 5-FU, folic acid, administered to enhance the effect of 
chemotherapy drugs, and OXA (FOLFOX) or IRI (FOLFIRI). I combined different 
concentration of the drugs and I have identified the best dose-effect concentration using the 
Compusyn software (Chou and Talalay, 1984; Supplementary tables 1-6). The 
concentrations of 5-FU combined with OXA and IRI I have selected are shown in Table 8.  
 
Table 8. Combined concentration of chemotherapy drugs obtained by Compusyn 
software 
 HT29 HCT116 HCT116P53-/- 
OXA + 5-FU 0.1 µM + 2.5 µM 0.385 µM + 0.85 µM 1.6 µM + 0.9 µM 
IRI + 5-FU 0.1 µM + 0.625 µM 0.048 µM + 0.425 µM 0.0325 µM + 0.45 µM 
 
Metformin was used at a concentration of 5 mM. Similarly to what was done for the 
experiments where metformin was combined with single drugs, I have tested different 
sequences of combined treatments with metformin, whose design is shown in Figure 9 of 
the Material and Methods chapter. 
 
4.2.2.1 Analysis of combinatorial treatments with metformin and oxaliplatin-5-FU regimen  
I observed that in the cell line HT29 the combination OXA-5FU reduced the 
viability of cells better than metformin administered alone (MET vs OXA-5FU, P value = 
0.0351) and the simultaneous administration of the regimen and metformin (OXA-5FU-
MET) was even more effective (OXA-5FU vs OXA-5FU-MET, P value = 0.0425; Figure 
24 A). When OXA-5FU regimen was administered prior metformin, for short or longer 
times (OXA-5FUàMET, (OXA-5FU)3àMET), the reduction of cell growth was 
comparable to that observed for treatment with only  metformin (MET). Similarly to what 
was observed in the combined treatment of metformin with 5-FU and OXA (Figure 21 A 
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and 22 A), when metformin was administered before the chemotherapy drug regimens 
(METàOXA-5FU and METà(OXA-5FU)3) reduction of cell viability was less evident.  
Metformin confirmed to be very effective in the HCT116 cell line. The biguanide was 
more efficient that chemotherapy in reducing cell viability and its administration alone, 
along with regimen (OXA-5FU-MET) or before regimen (METàOXA-5FU) was the most 
effective treatment in reducing cell viability (MET vs OXA-5FU, P value < 0.0001; Figure 
24 B). On the contrary, the regimen OXA-5FU administered before metformin, both for 
short or longer time reduced the effectiveness of the biguanide. Finally, the administration 
of OXA-5FU for three days after metformin had the same reduction in cell viability as the 
regimen alone, confirming the greater sensitivity of HCT116 cells to metformin that to the 
regimen.  
In HCT116P53-/- cells the OXA-5FU regimen was more effective than metformin 
administered alone (OXA-5FU vs MET, P value = 0.0132) and the combination OXA-
5FU-MET (OXA-5FU vs OXA-5FU-MET, P value = 0.0011; Figure 24 C). Indeed, 
administration of the regimen before metformin, at short and longer times (OXA-
5FUàMET and (OXA-5FU)3àMET) reduced cell viability more than the opposite 
treatments (METàOXA-5FU and METà(OXA-5FU)3 and OXA-5FUàMET vs 
METàOXA-5FU, P value = 0.0002;  (OXA-5FU)3àMET vs METà(OXA-5FU)3, P 
value < 0.0001). Exposure to the regimen for 3 days before metformin ((OXA-
5FU)3àMET) was the most effective treatment (OXA-5FU vs (OXA-5FU)3àMET, P 
value < 0.0001).  
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Figure 24. Effect of oxaliplatin-5-FU (OXA-5-FU) regimen and metformin treatments 
on cell viability. The cells were seeded in six replicates in a 96-well plate and treated with 
metformin and/or OXA-5FU regimen. Metformin was administered at a 5mM 
concentration in all the treatments. The regimen concentrations administered have been 
determined using the Compusyn software: 0.1 µM  (OXA) + 2.5 µM (5-FU) for HT29 
cells, 0.385 µM (OXA)  + 0.85 µM (5-FU) for the HCT116 cell line and 1.6 µM (OXA) + 
0.9 µM (5-FU) for HCT116P53-/- cells. The cell proliferation rate was measured using the 
MTT assay. The bars indicate the mean value ± SD of three independent experiments (*P 
< 0.05, **P < 0.01, ****P < 0.0001). 
 
In conclusion, metformin combined with regimen was the most effective treatment in 
reducing viability of HT29 cells, indicating a likely synergism. HCT116 cells were highly 
sensitive to metformin administered alone or in combination with the regimen and its 
effect was maintained also after one day exposition to the regimen. In HCT116P53-/- cells 
the regimen better reduced cell viability than metformin and the combinatorial treatment 
with the biguanide. 
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4.2.2.2 Analysis of combinatorial treatments with metformin and irinotecan-5-FU regimen  
I found that the regimen including irinotecan was very efficient in reducing the 
viability of HT29 cells, and the addition of metformin administered in combination with 
IRI-5-FU or after 1 day of treatment with the regimen, did not increase the effectiveness of 
the treatment (Figure 25 A). However, a prolonged exposure to IRI-5-FU followed by 
treatment with metformin ((IRI-5FU)3àMET) was the most effective treatment (IRI-5FU 
vs (IRI-5FU)3àMET, P value < 0.0001), while administration of metformin before IRI-
5FU greatly reduced the effects of the regimen. 
The cell line HCT116 was very sensitive both to metformin and IRI-5-FU regimen (Figure 
25 B). However, the addition of metformin to the regimen did not further reduce cell 
viability. The administration of metformin followed by longer exposure to chemotherapy 
regimen (METà(IRI-5FU)3) had the lowest reduction of viability. Although in 
HCT116P53-/- cell line the number or viable cells for all the tested treatment was higher 
than in HCT116 cells, a similar trend of response to the different treatments was observed. 
Moreover, in the TP53 null cell line the regimen administered for longer time before 
metformin (IRI-5FU vs (IRI-5FU)3àMET, P value = 0.0002; Figure 25 C) was the most 
effective treatment.  
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Figure 25. Effect of irinotecan-5-FU (IRI-5-FU) regimen and metformin treatments 
on cell viability. The cells were seeded in six replicates in a 96-well plate and treated with 
metformin and/or IRI-5FU regimen. Metformin was administered at a 5mM concentration 
in all the treatments.  The regimen concentrations administered have been determined 
using the Compusyn software: 0.1 µM  (IRI) + 0.625 µM (5-FU) for HT29 cells, 0.048 µM 
(IRI)  + 0.425 µM (5-FU) for the HCT116 cell line and 0.0325 µM (IRI) + 0.45 µM (5-FU) 
for HCT116P53-/- cells. The cell proliferation rate was measured using the MTT assay. 
The bars indicate the mean value ± SD of three independent experiments (**P < 0.01, 
***P < 0.001, ****P < 0.0001). 
 
In the HT29 cell line the addition of metformin increased the effects of the regimen only 
when it was administered after a long treatment with IRI-5FU. Both metformin and 
regimen, alone and in all the combinations, strongly affected cell viability of HCT116 cells 
and the sequential exposure to regimen and metformin for longer times was the most 
effective treatment. A similar trend was observed in the HCT116P53-/- cell line, although 
with a lower reduction of viability.  
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4.2.3 Summary of key findings 
• metformin is very effective in reducing viability of the HCT116 cell lines 
• administration of irinotecan (single or as regimen) for 3 days followed by 
metformin is the most effective treatment in all the cell lines (probably because 
they overexpress IRI target), while the opposite treatment is the worst 
• in HCT116 cell lines metformin and oxaliplatin administered together act 
synergistically on reducing viability  
• combined treatments of metformin with chemotherapeutic drugs can be more 
effective than the single biguanide only in some settings and cell lines 
 
4.3 Analysis of combinatorial treatments with metformin and targeted 
drugs 
I also combined metformin with selective inhibitors of specific proteins expressed 
in CRC. I decided to focus on in vitro models of BRAF-mutant CRC because this tumour 
type has worse prognosis and is poorly sensitive to standard treatments (Kopets et al., 
2015). The fact that BRAF-mutant CRCs are highly proliferating supports a possible action 
of metformin on blocking their growth. I selected three CRC cell lines, differing for their 
MMR activity, that when is defective can give microsatellite instability, or carrying 
different BRAF mutations: HT29 (microsatellite stable, MSS) and RKO (with defective 
MMR activity, microsatellite instable, MSI), both carrying the typical BRAF V600E 
mutation, and NCI-H508 cells (MSS) that are characterised by the rare BRAF G596R 
mutation, for which there are no specific treatments reported. I chose to use two CRC cell 
lines with the same mutation (BRAF V600E) but different in their MMR status because it 
has been recently demonstrated an association between MMR activity and clinical 
response: patients with MSI tumours are more responsive to immune checkpoint blockade 
than patients with MSS tumours (Le et al., 2015). I have treated the three cell lines with 
 	 79 
metformin in combination with vemurafenib, a selective inhibitor for BRAF V600E 
mutation, panitumumab (selective inhibitor for EGFR), dasatinib (Bcr-Abl and Src 
inhibitor), regorafenib (a multi-kinase inhibitor) and trametinib (MEK inhibitor; Table 9).  
Table 9. List of the target of drugs tested in combination with metformin 
Type of drug  Target gene 
Vemurafenib BRAF 
Panitumumab EGFR 
Dasatinib Bcr-Abl and Src  
Regorafenib VEGFR-1, -2, -3, TIE-1, KIT, RET, BRAF, PDGFR-β, FGFR 
Trametinib MEK1, MEK2 
 
Similarly to what I have done for testing the effects of the chemotherapy drugs on CRC 
cells, to identify the best concentration of the targeted drugs to administer in combination 
with metformin, I conducted MTT viability assays and treated each cell line for 72 hours 
with different concentrations of the drugs.  
For each cell line, I designed a specific concentration range of vemurafenib for the MTT 
test analysis, based on the data of Yang et al. in which HT29 cells were defined highly-
sensitive, RKO intermediate-sensitive and NCI-H508 low-sensitive to the drug (Yang et 
al., 2012). The concentration ranges that I selected were as follows: 7.75 nM – 0.248 µM 
for HT29 and 0.156 – 20 µM for RKO and NCI-H508. Similarly, HT29 and RKO cells 
(carrying the BRAF V600E mutation) are classified as resistant to anti-EGFR treatment, 
and NCI-H508 (BRAF G596R) as sensitive (Medico et al., 2015) and the concentration 
ranges I chose for the MTT analysis were: 0.54 nM - 10 µM for HT29 and RKO cells and 
0.01 nM – 0.34 nM for NCI-H508 cells. As expected, treatment with panitumumab did not 
change the viability of HT29 and RKO cells even at the highest concentrations, confirming 
their resistance to the drug. For dasatinib, regorafenib and trametinib I established the 
concentrations to test based on those recommended by their leaflet and I drew the 
following concentration ranges: 30 nM – 100 µM for dasatinib and regorafenib and 0.007 
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nM – 0.12 µM for trametinib. Finally, I performed MTT assays to evaluate the 
concentrations of metformin to use for RKO and NCI-H508 cell lines and tested a 
concentration range of 0.16 – 20 mM. The viability plots and the IC50 values identified are 
shown on Figure 26 and Table 10.  
 
 
 
Figure 26. Determination of the IC50 values for targeted drugs and metformin in the 
BRAF-mutant cell lines. HT29, RKO and NCI-H508 cell lines were seeded in six 
replicates in a 96-well plate and treated with targeted drugs at different concentrations:	
7.75 nM - 20 µM for vemurafenib, 0.003 - 10 µM for panitumumab, 30 nM – 100 µM for 
dasatinib and regorafenib, 0.007 nM – 0.12 µM for trametinib. The concentration range 
used for determining the IC50 values for metformin in RKO and NCI-H508 cells was 0.16 - 
20 mM. After 72 hours MTT assay was used to determine the cell viability. Results are 
representative of two independent experiments.  
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Figure 26. Determination of the IC50 values for targeted drugs and metformin in the 
BRAF-mutant cell lines. HT29, RKO and NCI-H508 cell lines were seeded in six 
replicates in a 96-well plate and treated with targeted drugs at different concentrations:	
7.75 nM - 20 µM for vemurafenib, 0.003 - 10 µM for panitumumab, 30 nM – 100 µM for 
dasatinib and regorafenib, 0.007 nM – 0.12 µM for trametinib. The concentration range 
used for determining the IC50 values for metformin in RKO and NCI-H508 cells was 0.16 - 
20 mM. After 72 hours MTT assay was used to determine the cell viability. Results are 
representative of two independent experiments.  
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Table 10. IC50 values of targeted drugs in the CRC cell lines analysed. 
 HT29 RKO NCI-H508 
vemurafenib 0.12 µM 7.5 µM 10 µM 
panitumumab - - 0.17 nM 
dasatinib 12.2 nM 12.5 µM 2.5 µM 
regorafenib 1.5 µM 3.12 µM 12.5 µM 
trametinib 0.5 nM 32 nM 0.5 nM 
metformin 5 mM 10 mM 5 mM 
 
Using the CompuSyn software, I studied the effects of the interactions of the different 
combinations of the drugs and metformin and identified the concentrations of each drug to 
administer to the different cell lines. The combined concentrations of targeted drugs and 
metformin with CI<1 I selected are shown in Table 11.  All the combinations dasatinib-
metformin tested on NCI-H508 cells showed only antagonism (CI>1; supplementary table 
7). 
Table 11. Combined concentrations of targeted drugs and metformin obtained by 
Compusyn software. 
 HT29 RKO NCI-H508 
vemurafenib + metformin 0.062 µM + 2.5 mM 7.5 µM + 5 mM 1.25 µM + 2.5 mM 
panitumumab + metformin - - 0.02 nM + 2.5 mM 
dasatinib + metformin 3.05 nM + 5 mM 6.25 µM + 2.5 mM - 
regorafenib + metformin 0.0976 µM + 1.25 mM 1.56 µM + 2.5 mM 1.56 µM + 1.25 mM 
trametinib + metformin 0.5 nM + 10 mM 8 nM + 5 mM 1 nM + 5 mM 
 
 	 83 
To evaluate the contribution of metformin in combinatorial therapies with these drugs I 
conducted biochemical analyses of the cells treated at the concentrations listed in table 10 
and 11, focusing on the specific proteins targeted by the drugs used. 
 
4.3.1 Analysis of changes in proteins from pathways deregulated in CRC 
 
4.3.1.1 Analysis of combinatorial treatments with metformin and vemurafenib 
In the HT29 cell line the concentrations of vemurafenib and metformin used in the 
combined treatment were lower than those used in the single treatments (the IC50 value 
obtained for each drug). In fact, I used 50% and a 25% of the IC50 concentrations of 
vemurafenib and of metformin respectively, obtaining 40% of cell death (Supplementary 
table 8). For RKO cells, where the mortality observed in the combined treatment was 
almost 90%, I maintained the IC50 concentration of vemurafenib and used 50% of the IC50 
concentration of metformin (Supplementary table 9). In NCI-H508 I used 12.5% and 50% 
of the IC50 concentrations of vemurafenib and metformin respectively, obtaining more than 
70% of cell death (Supplementary table 10).  
In the HT29 cell line metformin treatment decreased the phosphorylation of ERK1/2 
(Thr202/Tyr204) and blocked that of S6 protein (Ser240/244), while treatment with 
vemurafenib had a weak effect on the activity of ERK1/2 and S6 protein (Figure 27 A). 
Combined treatment including metformin and vemurafenib showed a reduction of ERK1/2 
and S6 protein activity but an increase of Akt phosphorylation (Ser473).  It has been 
reported that inhibition of the active BRAF-mutant (V600E) causes a feedback activation 
of EGFR in CRC (Corcoran et al., 2012; Prahallad et al., 2012) and for this reason I also 
evaluated the effects of vemurafenib on EGFR and found that vemurafenib administered 
alone reduced EGFR activity, while the concomitant addition of metformin increased 
EGFR phosphorylation.  
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Metformin alone markedly reduced the phosphorylation of ERK1/2, Akt and of S6 protein 
in RKO cells, while vemurafenib administered alone reduced the expression and activity of 
ERK1/2 and Akt (Figure 27 B). The combined treatment of vemurafenib with metformin 
reduced the activity of ERK1/2, Akt and of S6 protein; however, single treatment with 
metformin was more effective on all of them. RKO cells present low constitutive EGFR 
phosphorylation and for this reason I could not verify possible changes in this protein 
induced by the treatments.  
Metformin administered alone only reduced the activation of S6 protein in the NCI-H508 
cell line (Figure 27 C). Treatment with vemurafenib slightly reduced Akt and S6 protein 
activity and combined treatment of vemurafenib with metformin markedly decreased the 
phosphorylation of S6 protein, as a result of metformin treatment. As regards EGFR, both 
treatments reduced its phosphorylation and metformin seemed more effective than 
vemurafenib.   
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Figure 27. Effects of vemurafenib on cell signalling. HT29, RKO and NCI-H508 cell 
lines were left untreated or treated with metformin and vemurafenib at their respective IC50 
values (HT29: 5 mM metformin and 0.062 µM vemurafenib; RKO: 10 mM metformin and 
7.5 µM vemurafenib; NCI-H508: 5 mM metformin and 10 µM vemurafenib). The 
concentrations administered for the combined treatment were those determined using the 
Compusyn software (HT29: 2.5 mM metformin + 0.062 µM vemurafenib; RKO: 5 mM 
metformin + 7.5 µM vemurafenib; NCI-H508: 2.5 mM metformin + 1.25 µM 
vemurafenib). The treatments lasted for 72 hours. The combinatorial treatment of 
metformin and vemurafenib had no better effect than single treatments alone in all the cell 
lines analysed. Vinculin was used as the loading control. The results are representative of 
at least three independent experiments. 
 
In summary, in all cell lines combined treatment of vemurafenib and metformin had no 
better effect than single treatments.  
 
4.3.1.2 Analysis of combinatorial treatments with metformin and panitumumab 
Only the NCI-H508 cell line was sensitive to the drug. The combined treatment of 
panitumumab and metformin consisted in 12.5% of IC50 concentration of panitumumab, 
plus metformin given at 50% of its IC50 and led to almost 40% of cell death 
(Supplementary table 11). Panitumumab given alone only reduced the activity of its target 
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EGFR (Figure 28). Interestingly, also metformin reduced EGFR activity. The sumiltaneous 
administration of panitumumab and metformin blocked the activity of S6 protein (as result 
of treatment with metformin) and, most of all, of EGFR for which the two drugs seemed to 
have synergistic effect. 
 
 
Figure 28. Effects of panitumumab on cell signalling. NCI-H508 cell lines were left 
untreated or treated with metformin and panitumumab at their respective IC50 values (5 
mM metformin and 0.17 nM panitumumab). The concentrations administered for the 
combined treatment were those determined using the Compusyn software (2.5 mM 
metformin + 0.02 nM panitumumab). The treatments lasted for 72 hours. The 
combinatorial treatment of metformin and panitumumab reduced EGFR activation. 
Vinculin was used as the loading control. The results are representative of at least three 
independent experiments. 
 
4.3.1.3 Analysis of combinatorial treatments with metformin and dasatinib 
In combined treatments including dasatinib and metformin HT29 and RKO cells 
were treated with 25% and 50% of the concentrations of dasatinib and with 50% and 25% 
 	 87 
of that of metformin used for the single treatments respectively, and treatment resulted in 
50% and 60% of cell death (Supplementary tables 12 and 13).  
Metformin reduced the growth of HT29 cells and decreases the expression of all the 
proteins analysed (Figure 29 A). The biguanide strongly diminished the phosphorylation of 
ERK1/2 and Src and blocked that of S6 protein. Dasatinib administered alone only resulted 
in a slight reduction of Akt activation, but not of Src, one of its known targets. Combined 
treatment of dasatinib and metformin maintained the reduction of ERK1/2 and of S6 
protein activity induced by metformin, but did not reduce Src phosphorylation, suggesting 
that dasatinib antagonises the effect of metformin on Src. Similarly, metformin seemed to 
antagonise the reduction of Akt phosphorylation induced by dasatinib.  
In RKO cells metformin alone markedly reduced the phopshorylation of all the proteins 
analysed (Figure 29 B). Treatment with dasatinib decreased the activation of ERK1/2 and, 
even if with weaker intensity, of Akt and S6 protein. Block of Src phosphorylation was 
stronger than that obtained with metformin. This block was maintained when cells were 
treated with both the drugs; however, reduction of ERK1/2, Akt and S6 protein activity, 
seen with metformin alone, were not observed. 
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Figure 29. Effects of dasatinib on cell signalling. HT29 and RKO cell lines were left 
untreated or treated with metformin and dasatinib at their respective IC50 values (HT29: 5 
mM metformin and 12.2 nM dasatinib; RKO: 10 mM metformin and 12.5 µM dasatinib). 
The concentrations administered for the combined treatment were those determined using 
the Compusyn software (HT29: 5 mM metformin + 3.05 nM dasatinib; RKO: 2.5 mM 
metformin + 6.25 µM dasatinib). The treatments lasted for 72 hours. The combinatorial 
treatment of metformin and dasatinib reduced ERK activation in HT29. Vinculin was used 
as the loading control. The results are representative of at least three independent 
experiments. 
 
In HT29 cells the combination of dasatinib and metformin seemed to have better effect of 
the single treatments in reducing ERK1/2 phosphorylation, while in RKO cells the 
combined treatment did not reduce protein activity better than either drugs administered 
alone. 
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4.3.1.4 Analysis of combinatorial treatments with metformin and regorafenib 
Regorafenib and metformin administered together were given to HT29 cells at 
6.25% and 12.5% of the concentration s used in the individual treatments and resulted in 
40% cell death (Supplementary table 14). Similarly, RKO cells received 50% and 25% of 
the concentrations of regorafenib and metformin administered in the single treatments, 
with almost 70% of cell mortality (Supplementary table 15). As for NCI-H508 cells, they 
were treated with 12.5% and 25% of the concentrations of regorafenib and metformin 
given alone and the treatment gave more than 40% of cell death (Supplementary table 16).  
I have not been able to evaluate the effects of the combined treatment on the specific 
proteins targeted by regorafenib. I tested the expression of PDGFR-β and KIT, two target 
proteins of regorafenib, but the three cell lines I used do not express them. Thus, I assessed 
the effects of this combinatorial treatment by considering only changes in the activity of 
ERK1/2, Akt and S6 protein. Regorafenib did not affect the phosphorylation of ERK1/2, 
Akt and S6 protein in the HT29 cell line (Figure 30 A) and when combined with 
metformin it only reduced the activity of S6 protein, which was caused by the addiction of 
the biguanide (indeed, treatment with metformin alone inhibited S6 phosphorylation). 
Regorafenib did not change the activity of ERK1/2, Akt and S6 protein in RKO cells and 
when used in combination with metformin antagonised the effects of the biguanide, 
maintaining the phosphorylation of Akt and S6 protein (Figure 30 B). In NCI-H508 cells 
regorafenib reduced the phosphorylation of ERK1/2, Akt and also of S6 protein although 
the decrease of S6 protein activity was less than that observed with metformin (Figure 30 
C). Combined treatment with the two drugs significantly increased ERK1/2 activation, 
while phosphorylation of Akt and of S6 protein was similar to that of treatment with 
regorafenib. 
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Figure 30. Effects of regorafenib on cell signalling. HT29, RKO and NCI-H508 cell 
lines were left untreated or treated with metformin and regorafenib at their respective IC50 
values (HT29: 5 mM metformin and 1.5 µM regorafenib; RKO: 10 mM metformin and 
3.12 µM regorafenib; NCI-H508: 5 mM metformin and 12.5 µM regorafenib). The 
concentrations administered for the combined treatment were those determined using the 
Compusyn software (HT29: 1.25 mM metformin + 0.0976 µM regorafenib; RKO: 2.5 mM 
metformin + 1.56 µM regorafenib; NCI-H508: 1.25 mM metformin + 1.56 µM 
regorafenib). The treatments lasted for 72 hours. The combinatorial treatment of metformin 
and regorafenib was less effective than single treatments alone in all the cell lines. 
However treatemtn with regorafenib administered alone reduced the activation of ERK, 
Akt and S6 in NCI-H508 cells. Vinculin was used as the loading control. The results are 
representative of at least three independent experiments. 
 
In conclusion, in all cell lines analysed the combined treatment of regorafenib and 
metformin did not give a better effect than either drug alone. 
 
4.3.1.5 Analysis of combinatorial treatments with metformin and trametinib 
Trametinib in combination with metformin was administered to RKO cells using 
50% of the concentrations of both the drugs given in single treatments and led to more than 
70% cell death (Supplementary table 17). The concentrations used for the other two cell 
lines were still higher than the values administered in the individual treatments. HT29 cells 
received the same concentration of trametinib and two times that of metformin used for 
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individual treatments, while the NCI-H508 cells were treated with double the 
concentration of trametinib and with the same concentration of metformin given as a single 
treatment. Cell death was almost 80% for the HT29 cells and more than 50% for the cell 
line NCI-H508 (Supplementary tables 18 and 19).  
Trametinib reduced the activity of its target ERK1/2 and Akt in HT29 cells. Similar results 
were obtained when metformin was added, and the biguanide reduced the activity of S6 
protein (Figure 31 A). I also evaluated changes in the expression of c-Myc, a downstream 
target of ERK1/2: single treatment with trametinib reduced c-Myc expression, but its 
reduction was stronger in presence of metformin. Combined treatment gave similar results 
as the treatment with metformin.  
In the RKO cell line trametinib given alone reduced the activity of ERK1/2 and c-Myc 
expression but increased S6 phosphorylation (Figure 31 B). Combined treatment with 
trametinib and metformin abolished ERK1/2 activity and decreased c-Myc expression, 
however I observed a marked increase of Akt activity and no reduction of S6 protein 
activity. 
Trametinib slightly reduced the activity of ERK1/2 but increased S6 protein 
phosphorylation in NCI-H508 cells (Figure 31 C). The simultaneous administration of 
trametinib and metformin abolishes ERK1/2 activity, suggesting that it has a synergistic 
effect on the reduction of ERK1/2 phosphorylation. Block of the activity of S6 protein, 
caused by metformin, was also observed. Interestingly, no changes in c-Myc expression, 
even for treatment with metformin, were observed. 
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Figure 31. Effects of trametinib on cell signalling. HT29, RKO and NCI-H508 cell lines 
were left untreated or treated with metformin and trametinib at their respective IC50 values 
(HT29: 5 mM metformin and 0.5 nM trametinib; RKO: 10 mM metformin and 32 nM 
trametinib; NCI-H508: 5 mM metformin and 0.5 nM trametinib). The concentrations 
administered for the combined treatment were those determined using the Compusyn 
software (HT29: 10 mM metformin + 0.5 nM trametinib; RKO: 5 mM metformin 8 nM 
trametinib; NCI-H508: 5 mM metformin and 1 nM trametinib). The treatments lasted for 
72 hours. The combinatorial treatment of metformin and trametinib reduced ERK 
activation in NCI-H508 cells. Vinculin was used as the loading control. The results are 
representative of at least three independent experiments. 
 
In conclusion, combined treatment of trametinib and metformin was more effective than 
single treatments only in NCI-H508 cells, where it provoked the suppression of ERK1/2 
activation.  
 
4.3.2 Cell cycle analysis on combinatorial treatments 
I observed that the administration of metformin in combination with vemurafenib, 
dasatinib and trametinib to RKO cells, as well as that of metformin given together with 
vemurafenib in NCI-H508 cells strongly decreased cell viability. In fact, after 72 hours of 
treatment, metformin given in combination with vemurafenib, dasatinib and trametinib 
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reduced viability of more than 80%, about 60% and more than 70% respectively in RKO 
cells. In the NCI-H508 cell line the combinatorial treatment vemurafenib-metformin 
caused more than 70% of cell death.  
To investigate the cellular mechanisms that reduce viability, I decided to evaluate the 
changes in cell cycle progression induced by treatments including these drugs. In RKO 
cells, metformin treatment for 72 hours induced an accumulation of cells in the S phase (on 
average of 11.5%, specifically from 26.8% to 39.55% in the experiment with vemurafenib; 
from 29.23% to 43.40% in the experiment with dasatinib and from 20.85% to 28.74% in 
the experiment with trametinib; Figure 32 A-B-C) and in the G2/M phase (from 9.14% to 
19.11% in the experiment with vemurafenib; on average of 10.24%, from 10.36% to 
22.28% in the experiment with dasatinib and from 16.85% to 25.32% in the experiment 
with trametinib; Figure 32 A-B-C) respect to the untreated cells.  
Addition of vemurafenib, both alone and in combination with metformin, did not induced 
substantial variations in the cell cycle profiles (Figure 32 A). 
The DNA profiles of RKO cells treated with dasatinib alone or combined with metformin 
showed an increase in S phase (from 29.23% to 36.14% when dasatinib was administered 
alone and from 29.23% to 39.56% in the combined treatment; Figure 32 B).  
Treatments with trametinib caused a marked accumulation of cells in G0/G1 phase (from 
62.3% to 84.25% when trametibin was administered as single drug and from 62.3% to 
73.78% in combined treatment trametinib-metformin; Figure 32 C). Moreover when 
trametinib was administered as single treatment I observed a reduction in the percentage of 
the G2/M phase fraction (from 16.85% to 6.43%). 
In the NCI-H508 cell line treatment with metformin only resulted in a slight accumulation 
of cells in the S phase (from 24.63% to 30.79%), that I also observed after treatment with 
vemurafenib (from 24.63% to 33.24%) and which was confirmed in cells that had the 
combined treatment  (from 24.63% to 34.73%; Figure 32 D). 
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Figure 32. Cell cycle analysis in RKO and NCI-H508 cell lines treated with targeted 
drugs.  The two cell lines were left untreated or treated with metformin and targeted drugs 
at their respective IC50 values (RKO: 10 mM metformin, 7.5 µM vemurafenib, 12.5 µM 
dasatinib and 32 nM trametinib; NCI-H508: 5 mM metformin and 10 µM vemurafenib). 
The concentrations administered for the combined treatment were those determined using 
the Compusyn software (RKO: 5 mM metformin + 7.5 µM vemurafenib; 2.5 mM 
metformin + 6.25 µM dasatinib; 5 mM metformin + 8 nM trametinib.  NCI-H508: 2.5 mM 
metformin + 1.25 µM vemurafenib). The treatments lasted for 72 hours. In RKO cells 
metformin induced an accumulation in S and G2/M phases. Vemurafenib, alone or 
combined with metformin, did not induce changes in cell cycle profile. Treatment with 
Dasatinib caused an S phase increase, while Trametinib strongly increased G0/G1 phase. 
In NCI-H508 cells all treatments resulted in a slight accumulation of cells in S phase. 
Vinculin was used as the loading control. The results are representative of at least three 
independent experiments. 
 
In conclusion metformin seems to determine a block in S phase of RKO cell lines. The 
stronger effect of targeted drugs on cell cycle was observed, always in RKO, after 
trametinib treatments where the drug, alone or in combination with metformin, leads to a 
cells accumulation in G0/G1 phase. 
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4.3.3 Summary of key findings 
The combination of metformin with targeted drugs does not represent an advantage for 
treatment of BRAF-mutant CRC cell lines. 
In addition, I observed that: 
• metformin seems to be more effective in cells with high proliferation rate (RKO 
and HCT116) than those with slow growth (NCI-H508) 
• tumours with BRAF G596R mutation could benefit from treatment with 
regorafenib  
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CHAPTER 5 
DISCUSSION 
 
 
We investigated the role of metformin alone or in combination with other drugs as 
potential anticancer therapy in CRC by analysing its effects on four cell lines (HT29, 
HCT116, HCT116P53-/- and DLD-1) and on 3D-organoids we derived from a peritoneal 
carcinomatosis. Although previous studies have shown that metformin inhibits the 
proliferation of CRC cells (Zakikhani et al., 2008), the drug’s underlying mechanisms of 
action on CRC are still unclear. We found that metformin had a cytostatic effect, also on 
the stem component of the cells, but did not induce cell death. In addition, its effects were 
reversed after drug removal. In line with the observations in other types of cancer (Pierotti 
et al., 2013), the cytostatic effect of metformin appears to be determined by a reduction of 
cell proliferation, an increased accumulation of cells in G0/G1 phase, a decrease in the 
expression of proteins that regulate cell cycle progression such as cyclin D1 and c-Myc, 
and inhibited phosphorylation of the downstream target of cyclin D1, pRb.   
The results we obtained for the DLD-1 cell line were controversial. In these cells 
metformin caused reduction of cyclin D1, c-Myc, cyclin E expression and of 
phosphorylation of pRb; however there was only a very weak decrease of the cell 
proliferation after 24 hours of treatment and, most of all, changes in the cell cycle were not 
observed. The fact that both the alleles of LKB1 gene, the main activator of AMPK, are 
methylated in DLD-1 cells (Esteller et al., 2000) could, at least in part, explain these 
results. In fact, it has been demonstrated that LKB1 activity is required for cell cycle arrest 
in DLD-1 cells (Scott et al., 2007). Most of all, several studies have suggested that 
metformin can also act via activation of LKB1/AMPK-TSC1/TSC2 pathway and loss of 
LKB1 functions avoid the suppression of the mTOR-signaling pathway (Carretero et al., 
2007). Finally, a recent study, in which the addiction of metformin to DLD-1 cells grown 
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under glucose-deprived conditions caused inhibition of cell growth (Miyo et al., 2016), 
suggests that in this cell line metformin requires low glucose conditions to suppress tumour 
growth.  
We investigated whether the blockade of the cell cycle observed in the remaining cell lines 
and in the organoids could result in a permanent exit from the cell cycle or lead to cell 
death. Although in other types of cancer metformin promotes senescence, apoptosis or 
autophagy (Williams et al., 2013, Yi et al., 2013, Malki et al., 2011, Gao et al., 2016, 
Queiroz et al., 2014, Feng et al., 2014, Tomic et al., 2011), all the cell lines and the 
organoids analysed showed no permanent cytostatic effects or induction of cell death. 
Autophagy is a cellular process induced by deprivation of nutrients and growth factors, 
while we cultured the cells in complete media containing growth factors and nutrients that 
may have influenced the effects of metformin on our models. We used a standard culture 
medium containing 17 mM glucose; although several reports show that the biguanide 
induces apoptosis in this medium, there are data in breast cancer suggesting that metformin 
increases apoptotic cell death only in glucose deprivation conditions, while the presence of 
glucose causes cell cycle arrest (Wahdan-Alaswad et al., 2013, Menendez et al., 2012). As 
for CRC, Buzzai et al. reported that under nutrients deprivation, metformin can promote 
autophagy in CRC cell lines with wild type TP53, while it can induce apoptosis in TP53-
deficient cells (Buzzai et al., 2007). The cell lines and the organoids we used were either 
TP53 wild-type (HCT116 cells) or mutant (HT29 and DLD-1 cells and also organoids) and 
HCT116P53-/- cells had deletion of both the alleles of the gene, but we did not observe 
changes in the regulation of cell death related to the TP53 status of the cell lines. Most 
likely, the presence of nutrients could have exceeded the effects of metformin on these 
cells. 
It has also been suggested that metformin may induce apoptosis when cells are seeded 
almost at confluence (Silvestri et al., 2015). We worked under low-density conditions 
(5×104 cells/cm2) because it is required for carrying out drug sensitivity assays. In addition, 
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the drug induced a high degree of acidosis (a decrease in pH from 8 to 6.5) at a higher 
density (1.5×105 cells/cm2), which may interfere with its effects. However, we did not 
observe apoptosis even under acidosis conditions (data not shown). 
As for the effects of metformin on cell senescence, they have not yet been clarified and 
conflicting literature data have reported. In fact it has been demonstrated that metformin 
can induce TP53-dependent senescence in hepatoma cells (Yi et al., 2013) and in a triple 
negative breast cancer model (Williams et al., 2013), while Moiseeva et al., reported that 
metformin reduced the expression of pro-inflammatory cytokines implicated in the 
senescence process (Moiseeva et al., 2013). 
A clonogenic assay showed that in HT29, HCT116 and HCT116P53-/- cells the cytostatic 
effect of metformin was transient and that cells treated with metformin even for 18 days, 
were still able to form new colonies in fresh complete medium after drug removal. 
HCT116P53-/- cells made more effort to revert this transient effect, thus suggesting that 
metformin is more effective in the absence of TTP53. As for DLD-1 cells, their clonogenic 
capacity was similar at all the time points analysed, which is in agreement with the absence 
of cell cycle arrest observed. However, it seems to contradict the immunoblotting data for 
cyclins D1 and E and for c-Myc, as well as pRB phosphorylation, which are all decreased 
by the treatment. These results suggest that metformin is only partially effective on these 
cells and acts only on some routes, which are offset from others and finally result in cell 
growth.  The fact that DLD-1 cells have both the alleles of LKB1 gene inactivated (which 
is one of the targets of metformin) could contribute to give the observed results. Overall, 
the results we obtained on DLD-1 cells do not fully support an effect of the biguanide on 
them, at least at the concentrations used, and for this reason we decided to examine in 
more detail the effect of metformin only on the other cell lines and on the organoids. 
The anti-proliferative action of metformin observed in HT29 and HCT116 and 
HCT116P53-/- cells and organoids seems to be mainly mediated by the inactivation of the 
mTOR pathway and IGF1R protein (Pierotti et al., 2013), both playing a critical role in cell 
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growth, and that are often deregulated in patients with various cancers (including CRC). 
Metformin reduced the phosphorylation of mTOR, of its downstream effectors (ribosome 
protein S6 and 4E-BP1) and of IGF1R. Interestingly, the inhibition of mTOR was also 
observed in the HCT116 and HCT116P53-/- cells in which AMPK was not activated, thus 
suggesting that metformin arrests cell growth in CRC cells through mechanisms different 
than activation of AMPK. There are in fact other pathways, such as RAG GTPase or 
REDD1 that are known to inhibit mTOR signalling after treatment with metformin 
(Kalender et al., 2010, Ben Sahra et al., 2011). Metformin may also reversibly inhibit 
complex I of the mitochondrial respiratory chain and stimulate the production of ROS, 
which induce cell cycle arrest (Marchi et al., 2012), thus providing an alternative 
mechanism to AMPK activation (Bridges et al., 2014, Biswas et al., 2006, Mackenzie et 
al., 2013).  
The reversible effect of metformin on cell proliferation observed in the clonogenic assays 
was confirmed by the finding that mTOR pathway and IGF1R were completely restored 
after metformin removal and growth in fresh complete medium, without the drug.  
The results obtained show that metformin can transiently inhibit the growth and 
proliferation of CRC, thus suggesting that it is not suitable for the treatment of cancer. 
Therefore we decided to design strategies that combine metformin with other drugs that 
can benefit from the inhibition of cell growth functions induced by the biguanide and 
promote cell death. 
The majority of the chemotherapeutic drugs currently used for the treatment of CRC 
function damaging cells during the S phase of the cell cycle: the antimetabolite 5-FU 
interferes with DNA synthesis, the alkylating agent oxaliplatin directly damages DNA and 
the topoisomerase inhibitor irinotecan blocks DNA replication. We designed settings in 
which metformin and the chemotherapeutic drugs (given alone or in regimen combination) 
were administered in different combinations and for different times. We also tested longer 
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exposures to chemotherapy that can mimic the typical environment of patients undergoing 
prolonged treatment planning. 
The addition of metformin to chemotherapy is controversial and in some cases appears to 
potentiate (Dong et al., 2012, Kim et al., 2014, Illiopulos et al., 2011), in others to 
antagonise (Janjetovic et al., 2011), the effects of chemotherapeutic drugs.  
Irinotecan significantly decreased the viability in all the cell lines and its administration 
before metformin, especially for longer times, was the most effective treatment. The fact 
that topoisomerase I, the direct target of the drug, is highly expressed in CRC (Boonsong et 
al., 2002) may explain the sensitivity of these cells to the drug. Because of its cytostatic 
effect on CRC, metformin added after irinotecan may prevent the repair of the DNA breaks 
induced by the drug, driving damaged cells to death. In addition, in CRC the treatment 
with irinotecan appears to be associated with reduction of the stem cells markers CD44, 
CD166 and Lgr5 (Dylla et al., 2008, Emmink et al., 2011), which are also targeted by 
metformin. Since the stem component of tumours is considered the chemo-resistant 
fraction of cancer, its eradication could explain the high response of these cells to the drug.  
On the contrary, metformin given before irinotecan seems to antagonise the 
chemotherapeutic drug. Most likely, the cytostatic effect of metformin lasts after its 
removal and prevents irinotecan to function. The same conclusions can be achieved when 
metformin is added before longer exposure to most of treatments including 5-FU or 
oxaliplatin. 
Other differences observed reflect the individual sensitivity of the cells to the 
chemotherapeutic drugs. Metformin co-administered with 5-FU or oxaliplatin has a 
synergistic effect in HCT116 and HCT116P53-/- cell lines, while the oxaliplatin-5-FU 
regimen gives opposite results. In fact, HCT116 cells are more sensitive to metformin than 
to oxaliplatin-5-FU regimen, suggesting that the biguanide drives reduction of cell viability 
in the combinatorial treatment. This result is supported by the finding that oxaliplatin-5-FU 
regimen given before metformin cannot induce growth arrest. On the contrary, 
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HCT116P53-/- cells are more sensitive to oxaliplatin-5-FU regimen than to metformin and 
a longer administration of the regimen before the biguanide better reduces cell 
proliferation. Maybe these differences could be related to apoptosis induction. 
The different response obtained with chemotherapy can be also attributed to the different 
status of TP53. It was reported that gain of function mutation on TP53, such as R273H 
present in HT29, or loss of TP53 gene (in HCT116P53-/- cells) can confer resistance to 
different chemotherapeutic drugs including anti-metabolites, DNA cross-linking agents 
and topoisomerase inhibitors (Lowe et al., 1993, O’Connor et al., 1997, Boyer et al., 2004, 
Brosh et al., 2009, Fan et al., 1994, Blandino et al., 1999, Chang et al., 2001, Cabelguenne 
et al., 2000), although other authors showed that mutant TP53 displays sensitivity to 
chemotherapy (Fan et al., 1995, Bradford et al., 2003, Jackson et al., 2013). Our data 
highlight that the TP53 status could be linked to different responses to chemotherapy. As 
shown in table 7, TP53-mutant HT29 cells are less sensitive to 5-FU and irinotecan. In 
accordance with Boyer et al. in our experiment HCT116P53-/- cells were the most 
resistant to oxaliplatin (Boyer et al., 2004). HCT116 cells (TP53 WT) were the most 
sensitive for all the drugs tested and it has been reported that sensitivity to 5-FU and 
oxaliplatin was a characteristic of TP53 WT CRC cells (Boyer et al., 2004, Toscano et al., 
2007, Bunz et al., 1999). This can be explained considering that most of the 
chemotherapeutic drugs are anti-apoptotic agents and mutations in the apoptosis pathway, 
in which TP53 protein is one of the main players, can protect cancer cells from death. 
Our data highlight that HCT116 and HCT116P53-/- are very sensitive to metformin; both 
cells have a fast growth and the biguanide may better exert its cytostatic function. In 
combined treatments metformin added after chemotherapy increases cell death, most likely 
because its cytostatic effect avoids the repair of DNA damage. The most effective 
treatment consists of metformin combined with irinotecan. Indeed trials that will establish 
the clinical relevance of metformin plus irinotecan combination in CRC patients 
(NCT01930864, on refractory CRC) have been already activated. 
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Finally we tested metformin in combination with targeted drugs on BRAF-mutant cell 
lines. Although at first these drugs show a great response rate, resistance develops in a 
short period of time. Among novel potential therapeutic options, the association of targeted 
drugs with regulators of the metabolism could be a promising strategy to overcome the 
inevitable resistance.  
The analysis of changes in proteins from pathways deregulated in CRC, and potentially 
target of the drugs tested, showed that the combination of metformin with vemurafenib 
(which inhibits V600E-mutant BRAF) increased the phosphorylation of Akt and of EGFR 
in HT29 and RKO cells, suggesting antagonism between the two drugs. The drug made no 
protein alterations in NCI-H508 cells (G596R-mutant BRAF) and the reduced activity of 
EGFR and of S6 protein observed in the combined treatment was driven by metformin. 
Furthermore, dual treatment induced no modifications of the cell cycle phases in any of the 
tested cell lines (RKO and NCI-H508). It has been shown that the combination with 
metformin and vemurafenib inhibits mTOR signalling, induces cell cycle arrest in G1 
phase and apoptosis in BRAF V600E-mutant melanoma cell lines, and in vivo results in 
tumour regression (Niehr et al., 2011, Yuan et al., 2013). Similar findings were also 
obtained in BRAF V600E-mutant thyroid cancer cell lines (Hanly et al., 2015). One 
possible explanation of our results may be that HT29 and RKO cell lines are mutated in the 
PIK3CA gene (Ikenoue et al., 2005) and resistance to vemurafenib in BRAF V600E-
mutant CRC cells has been associated with the presence of PIK3CA mutations that hyper-
activate the PI3K/Akt pathway (Mao et al., 2013). Although metformin strongly inhibited 
Akt activation in RKO cells, its administration with vemurafenib hampers this effect. 
Metformin combined with the EGFR inhibitor panitumumab in NCI-H508 cell line 
abolished the phosphorylation of EGFR, but maintained active the downstream proteins 
Akt and ERK1/2.  
Combinatorial treatment with the Src inhibitor dasatinib and metformin reduced the 
activation of ERK1/2 but increased Src phosphorylation in HT29 cells. As for the RKO 
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cell line, the drug administered with metformin slightly increased the S phase of the cell 
cycle, but the two drugs given together only showed reduction of EGFR activity. Lin et al. 
reported that metformin synergizes with dasatinib in head and neck squamous cell 
carcinoma cells, through AMPK-mediated energy stress (Lin et al., 2014). Further analyses 
of this pathway on our cells could help in understanding the effects of the dual treatment in 
CRC. 
As for the combinatorial treatment with metformin and the multi-kinase inhibitor 
regorafenib, it had no advantages compared to the individual drugs in all the cell lines. In a 
recent paper on non-small cell lung cancer, in which metformin was combined with 
sorafenib (another multi-kinase inhibitor), the authors report a synergistic growth 
inhibition induced by AMPK activation and inhibition of mTOR pathway (Groenendijk et 
al., 2015). This is in agreement with our observation that the combined treatment reduced 
activation of the S6 protein in HT29 and NCI-H508 cells. Regorafenib administered alone 
also reduced ERK1/2 and Akt activation in NCI-H508 cells; however, the combinatorial 
treatment with metformin antagonizes this effect.  
The combination of metformin with trametinib, a MAPK inhibitor, had a synergistic 
effects only in NCI-H508 cells, where it suppressed the activation of ERK1/2 and of S6 
protein. Similar results were reported in NRAS-mutant cell lines from melanoma, lung 
cancer and neuroblastoma, where also phosphorylation of Akt was reduced (Vujic et al., 
2015). The reduction of cell viability we observed in RKO cells was similar to that 
described by these authors and is in line with the increase of G0/G1 phase we observed. 
These results suggest that in BRAF-mutant CRC cells the combined therapy does not 
provide advantages over the one with the individual drugs. We found that RKO cells are 
very sensitive to metformin, most likely because of their fast growth that, as for HCT116 
and HCT116P53-/- cells, may be targeted the biguanide. On the contrary, the fact that 
NCI-H508 cells grow very slowly could explain their weak response to metformin. As for 
NCI-H508 cells, the rare BRAF mutation they carry results in CRCs with different 
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characteristics compared to V600E-mutant tumours and for which there are no specific 
treatment recommendations (Cremolini et al., 2015). We have confirmed that treatment 
with anti-EGFR drugs reduced EGFR activity (Misale et al., 2014); however panitumumab 
did not diminished Akt and ERK1/2 phosphorylation. Instead our data have shown 
sensitivity of NCI-H508 cells to regorafenib, which decreases the phosphorylation of 
ERK1/2, Akt and of S6 protein. 
 
Overall, our results show that metformin is cytostatic on CRC cells. They have different 
responses to treatment with the biguanide, administered either in single or in combined 
treatments, which are mainly related to their molecular and physiological characteristics. 
The experiments with the standard chemotherapy drugs highlight that the efficacy of 
combined treatments strongly hangs on the sequence in which the drugs are given and that, 
in some settings the biguanide can even antagonise the effects of chemotherapy. 
Antagonism has been observed also when metformin has been simultaneously 
administered with target drugs. Although further investigations are still needed to elucidate 
the results of the treatments including metformin, these data suggest that caution should be 
used in administering chemotherapy to indviduals taking metformin.   
 
Summary of novel findings  
The novel findings emerged from this work can be summarised in three main points: 
• the effect of metformin on the block of cell proliferation is only temporary and 
does not make the drug suitable for the treatment of CRC 
• the effectiveness of the combinatorial treatments with metformin and 
chemotherapeutic drugs depends on the characteristics of the cells and on the 
sequence in which the drugs are administered. This result suggests that caution 
should be used in administering chemotherapy in patients taking metformin 
• the combination of metformin with targeted drugs do not represent an advantage 
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for the treatment of BRAF-mutant CRC and the assessment of the mutational status 
and of the proliferation rate of a tumor could help design effective therapeutic 
strategies 
 
 
Summary of future directions 
• study of the molecular mechanisms through which metformin induces cell growth 
arrest 
• analysis of variations in the molecular pathways altered by metformin and standard 
chemotherapy and regimens (i.e. activation/inhibition of apoptosis or DDR?) 
• In vivo experiments to examine response to the best combinatorial treatments 
identified in vitro. 
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Supplementary table 1. CI of oxaliplatin (OXA) and 5-FU in HT29  
OXA (µM) 5FU (µM) Effect CI 
0.05625 0.625 0.09564 1.96317 
0.1125 0.625 0.16982 1.03385 
0.225 0.625 0.22237 0.99194 
0.45 0.625 0.39984 0.88434 
0.9 0.625 0.54912 1.20393 
1.8 0.625 0.66040 1.90164 
0.05625 1.25 0.23311 0.99213 
0.1125 1.25 0.28289 0.83941 
0.225 1.25 0.32710 0.88088 
0.45 1.25 0.46769 0.86205 
0.9 1.25 0.56914 1.21982 
1.8 1.25 0.66752 1.91018 
0.05625 2.5 0.39873 0.70364 
0.1125 2.5 0.40192 0.78356 
0.225 2.5 0.41970 0.89883 
0.45 2.5 0.51196 0.93700 
0.9 2.5 0.62016 1.18816 
1.8 2.5 0.79140 1.46732 
0.05625 5 0.46309 0.94442 
0.1125 5 0.45345 1.07502 
0.225 5 0.51032 0.97346 
0.45 5 0.55096 1.10541 
0.9 5 0.60396 1.43681 
1.8 5 0.66711 0.89847 
0.05625 10 0.54966 1.15697 
0.1125 10 0.57032 1.10821 
0.225 10 0.59374 1.11731 
0.45 10 0.59651 1.36476 
0.9 10 0.64948 1.57457 
1.8 10 0.68355 2.29212 
0.05625 20 0.64491 1.33933 
0.1125 20 0.63015 1.5162 
0.225 20 0.64917 1.48603 
0.45 20 0.66258 1.61732 
0.9 20 0.66765 2.03844 
1.8 20 0.70982 2.5537 
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Supplementary table 2. CI of oxaliplatin (OXA) and 5-FU in HCT116 
OXA (µM)  5FU (µM) Effect  CI 
0.04813 0.425 0.13023 1.71477 
0.09625 0.425 0.12901 1.95370 
0.1925 0.425 0.19850 1.38384 
0.385 0.425 0.36670 0.94079 
0.77 0.425 0.45496 0.85006 
1.54 0.425 0.74689 0.94602 
0.04813 0.85 0.28469 0.93977 
0.09625 0.85 0.35163 0.73143 
0.1925 0.85 0.35959 0.87814 
0.385 0.85 0.42651 0.80087 
0.77 0.85 0.47975 1.14181 
1.54 0.85 0.73619 1.01544 
0.04813 1.7 0.50129 1.19280 
0.09625 1.7 0.42165 0.89477 
0.1925 1.7 0.46137 0.86871 
0.385 1.7 0.40472 1.43658 
0.77 1.7 0.53039 1.29635 
1.54 1.7 0.75114 1.01771 
0.04813 3.4 0.44143 1.41429 
0.09625 3.4 0.40778 1.76489 
0.1925 3.4 0.44354 1.60674 
0.385 3.4 0.52458 1.31171 
0.77 3.4 0.59761 1.31450 
1.54 3.4 0.74859 1.14545 
0.04813 6.8 0.59737 1.21952 
0.09625 6.8 0.58927 1.32015 
0.1925 6.8 0.57553 1.51528 
0.385 6.8 0.60801 1.46091 
0.77 6.8 0.68104 1.29712 
1.54 6.8 0.80451 1.03865 
0.04813 13.6 0.71813 1.18423 
0.09625 13.6 0.70558 1.31512 
0.1925 13.6 0.70254 1.40653 
0.385 13.6 0.72687 1.33398 
0.77 13.6 0.77568 1.18271 
1.54 13.6 0.80725 1.32269 						
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Supplementary table 3. CI of oxaliplatin (OXA) and 5-FU in	HCT116P53-/- 
OXA (µM)  5FU (µM) Effect  CI 
0.2 0.45 0.12132 0.94304 
0.4 0.45 0.14612 1.16563 
0.8 0.45 0.26093 1.0702 
1.6 0.45 0.48535 0.90065 
3.2 0.45 0.75327 0.69611 
6.4 0.45 0.78022 1.22498 
0.2 0.9 0.15712 1.05066 
0.4 0.9 0.27193 0.74527 
0.8 0.9 0.34036 0.89162 
1.6 0.9 0.57905 0.70383 
3.2 0.9 0.70937 0.84828 
6.4 0.9 0.80048 1.12485 
0.2 1.8 0.15742 1.72681 
0.4 1.8 0.21458 1.43821 
0.8 1.8 0.32843 1.16485 
1.6 1.8 0.50682 0.99238 
3.2 1.8 0.65657 1.07909 
6.4 1.8 0.80001 1.14943 
0.2 3.6 0.28606 1.36099 
0.4 3.6 0.38728 0.98223 
0.8 3.6 0.40973 1.16085 
1.6 3.6 0.54791 1.03123 
3.2 3.6 0.66030 1.16355 
6.4 3.6 0.74436 1.53901 
0.2 7.2 0.50150 0.92604 
0.4 7.2 0.52230 0.94060 
0.8 7.2 0.54544 1.02854 
1.6 7.2 0.64052 0.95218 
3.2 7.2 0.67003 1.31016 
6.4 7.2 0.75270 1.60488 
0.2 14.4 0.63110 0.97826 
0.4 14.4 0.66501 0.89064 
0.8 14.4 0.64558 1.10379 
1.6 14.4 0.71850 0.97392 
3.2 14.4 0.73184 1.2836 
6.4 14.4 0.77277 1.67595 					
 	 139 
				
Supplementary table 4. CI of irinotecan (IRI) and 5-FU in HT29 
IRI (µM)  5FU (µM) Effect  CI 
0.0125 0.625 0.20188 1.19559 
0.025 0.625 0.28624 0.87777 
0.05 0.625 0.38511 0.76966 
0.1 0.625 0.52384 0.67709 
0.2 0.625 0.57480 0.98324 
0.4 0.625 0.69722 1.0373 
0.0125 1.25 0.32059 0.89699 
0.025 1.25 0.33358 0.99866 
0.05 1.25 0.43342 0.79309 
0.1 1.25 0.47239 1.00814 
0.2 1.25 0.44486 1.94979 
0.4 1.25 0.56899 2.0199 
0.0125 2.5 0.36885 1.21428 
0.025 2.5 0.43050 0.96919 
0.05 2.5 0.45364 1.05001 
0.1 2.5 0.43364 1.58445 
0.2 2.5 0.41019 2.71896 
0.4 2.5 0.61622 1.75518 
0.0125 5.0 0.53050 0.94344 
0.025 5.0 0.53238 1.00175 
0.05 5.0 0.54587 1.05994 
0.1 5.0 0.49741 1.68143 
0.2 5.0 0.48411 2.4706 
0.4 5.0 0.57960 2.42407 
0.0125 10.0 0.45335 2.76143 
0.025 10.0 0.42683 3.30226 
0.05 10.0 0.40344 4.00003 
0.1 10.0 0.36839 5.43853 
0.2 10.0 0.38619 5.97202 
0.4 10.0 0.34178 10.2121 
0.0125 20.0 0.64975 1.82307 
0.025 20.0 0.64208 1.9488 
0.05 20.0 0.62245 2.27395 
0.1 20.0 0.62426 2.4292 
0.2 20.0 0.63367 2.64479 
0.4 20.0 0.63833 3.24495 					
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Supplementary table 5. CI of irinotecan (IRI) and 5-FU in HCT116 
IRI (µM)  5FU (µM) Effect  CI 
0.0015 0.425 0.18575 1.40433 
0.0030 0.425 0.21204 1.36419 
0.0060 0.425 0.28993 1.05359 
0.012 0.425 0.43334 0.71247 
0.024 0.425 0.55286 0.66790 
0.048 0.425 0.73619 0.45101 
0.0015 0.85 0.28469 1.03905 
0.0030 0.85 0.35163 0.75232 
0.0060 0.85 0.35959 0.92276 
0.012 0.85 0.45496 0.76590 
0.024 0.85 0.50129 0.98058 
0.048 0.85 0.75114 0.44058 
0.0015 1.7 0.42651 0.71657 
0.0030 1.7 0.42165 0.81362 
0.0060 1.7 0.46137 0.75473 
0.012 1.7 0.40472 1.39465 
0.024 1.7 0.53039 1.00151 
0.048 1.7 0.74859 0.51883 
0.0015 3.4 0.44143 1.23593 
0.0030 3.4 0.40778 1.61735 
0.0060 3.4 0.44354 1.41777 
0.012 3.4 0.52458 1.03164 
0.024 3.4 0.59761 0.89586 
0.048 3.4 0.80451 0.41527 
0.0015 6.8 0.59737 0.88341 
0.0030 6.8 0.58927 0.96249 
0.0060 6.8 0.57553 1.11849 
0.024 6.8 0.77568 0.59720 
0.048 6.8 0.62574 0.84855 
0.012 6.8 0.60801 1.01727 
0.024 13.6 0.68104 0.76945 
0.0015 13.6 0.71813 0.73401 
0.0030 13.6 0.70558 0.82485 
0.0060 13.6 0.70254 0.87619 
0.012 13.6 0.72687 0.78068 
0.048 13.6 0.80725 0.56754 					
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Supplementary table 6. CI of irinotecan (IRI) and 5-FU in HCT116P53-/- 
IRI (µM) 5FU (µM) Effect CI 
0.008125 0.45 0.17644 1.48995 
0.01625 0.45 0.30111 0.88533 
0.0325 0.45 0.43565 0.64213 
0.065 0.45 0.46080 1.01865 
0.13 0.45 0.49643 1.55827 
0.26 0.45 0.54184 2.27398 
0.008125 0.9 0.25272 0.97661 
0.01625 0.9 0.29725 1.08331 
0.0325 0.9 0.41959 0.80505 
0.065 0.9 0.51143 0.79968 
0.13 0.9 0.48701 1.72407 
0.26 0.9 0.51213 2.81766 
0.008125 1.8 0.31988 0.92245 
0.01625 1.8 0.37022 0.90663 
0.0325 1.8 0.43893 0.88565 
0.065 1.8 0.52520 0.84941 
0.13 1.8 0.50276 1.68777 
0.26 1.8 0.55133 2.29115 
0.008125 3.6 0.43879 0.82109 
0.01625 3.6 0.46062 0.85509 
0.0325 3.6 0.50465 0.86022 
0.065 3.6 0.54128 0.98549 
0.13 3.6 0.53956 1.55871 
0.26 3.6 0.55448 2.44694 
0.008125 7.2 0.45113 1.41969 
0.01625 7.2 0.51210 1.14761 
0.0325 7.2 0.47562 1.58389 
0.065 7.2 0.48736 1.88778 
0.13 7.2 0.51106 2.34088 
0.26 7.2 0.55698 2.80721 
0.008125 14.4 0.60565 1.3135 
0.01625 14.4 0.62484 1.23561 
0.0325 14.4 0.58862 1.57857 
0.065 14.4 0.57567 1.90519 
0.13 14.4 0.57027 2.41896 
0.26 14.4 0.59789 2.84657 
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Supplementary table 7. CI of dasatinib (DAS) and metformin (MET) in NCI-H508 
DAS (µM) MET Effect CI 
0.1565 0.3125 0.16166 0.39302 
0.3125 0.3125 0.13435 0.87186 
0.625 0.3125 0.02366 13.2395 
1.25 0.3125 0.14549 3 
2.5 0.3125 0.33563 1.66 
5.0 0.3125 0.57831 1.06 
0.1565 0.625 0.03837 2.16 
0.3125 0.625 0.24120 0.49199 
0.625 0.625 0.08332 3.1 
1.25 0.625 0.31138 1.04 
2.5 0.625 0.40310 1.26 
5.0 0.625 0.58898 1.05 
0.1565 1.25 1.0E-5 25208.4 
0.3125 1.25 0.01335 13.69 
0.625 1.25 1.0E-5 100635 
1.25 1.25 0.08731 5.86 
2.5 1.25 0.33488 1.86 
5.0 1.25 0.47889 1.81 
0.1565 2.5 0.09680 1.49 
0.3125 2.5 0.13610 1.54 
0.625 2.5 0.13067 2.40 
1.25 2.5 0.26000 1.8 
2.5 2.5 0.29602 2.52 
5.0 2.5 0.47414 2.06 
0.1565 5.0 0.21914 1.47 
0.3125 5.0 0.32408 1.26 
0.625 5.0 0.32716 1.46 
1.25 5.0 0.39520 1.53 
2.5 5.0 0.40354 2.07 
5.0 5.0 0.48768 2.36 
0.1565 10.0 0.61281 1.40 
0.3125 10.0 0.62666 1.39 
0.625 10.0 0.59069 1.54 
1.25 10.0 0.63911 1.50 
2.5 10.0 0.62626 1.75 
5.0 10.0 0.69454 1.77 
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Supplementary table 8. CI of vemurafenib (VEM) and metformin (MET) in HT29 
VEM (µM) MET Effect CI 
0.00775 0.625 0.08410 0.22357 
0.0155 0.625 0.11584 0.29471 
0.031 0.625 0.18937 0.41582 
0.062 0.625 0.34926 0.60948 
0.124 0.625 0.39064 1.09996 
0.248 0.625 0.51469 1.90565 
0.00775 1.25 0.05157 0.40257 
0.0155 1.25 0.20119 0.34405 
0.031 1.25 0.18864 0.51169 
0.062 1.25 0.30976 0.71340 
0.124 1.25 0.42971 1.12861 
0.248 1.25 0.54107 1.92094 
0.00775 2.5 0.12484 0.52979 
0.0155 2.5 0.23666 0.50135 
0.031 2.5 0.32204 0.58397 
0.062 2.5 0.40377 0.78716 
0.124 2.5 0.48307 1.20158 
0.248 2.5 0.59613 1.93811 
0.00775 5.0 0.24987 0.76086 
0.0155 5.0 0.30921 0.76865 
0.031 5.0 0.38270 0.83123 
0.062 5.0 0.48409 0.98005 
0.124 5.0 0.52456 1.39727 
0.248 5.0 0.65038 2.04627 
0.00775 10.0 0.40462 1.17715 
0.0155 10.0 0.45752 1.16633 
0.031 10.0 0.49979 1.22793 
0.062 10.0 0.56300 1.36476 
0.124 10.0 0.63354 1.67552 
0.248 10.0 0.71699 2.28235 
0.00775 20.0 0.69129 1.61766 
0.0155 20.0 0.70492 1.63571 
0.031 20.0 0.73308 1.6647 
0.062 20.0 0.74518 1.82002 
0.124 20.0 0.79068 2.04457 
0.248 20.0 0.84160 2.51547 
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Supplementary table 9. CI of vemurafenib (VEM) and metformin (MET) in RKO 
VEM (µM) MET Effect CI 
0.46875 0.625 0.41893 0.57519 
0.9375 0.625 0.48005 0.59736 
1.875 0.625 0.43184 1.26809 
3.75 0.625 0.51202 1.41167 
7.5 0.625 0.61877 1.39345 
15.0 0.625 0.95259 0.06829 
0.46875 1.25 0.34719 1.31258 
0.9375 1.25 0.41480 1.17664 
1.875 1.25 0.37563 2.15231 
3.75 1.25 0.45555 2.21457 
7.5 1.25 0.61605 1.53534 
15.0 1.25 0.94402 0.09498 
0.46875 2.5 0.63387 0.50475 
0.9375 2.5 0.66130 0.49529 
1.875 2.5 0.71810 0.43529 
3.75 2.5 0.75384 0.46746 
7.5 2.5 0.82736 0.38528 
15.0 2.5 0.99999 9.85E-7 
0.46875 5.0 0.68793 0.69633 
0.9375 5.0 0.68875 0.74359 
1.875 5.0 0.71502 0.72004 
3.75 5.0 0.83131 0.36846 
7.5 5.0 0.87812 0.29635 
15.0 5.0 0.91392 0.25703 
0.46875 10.0 0.83887 0.47127 
0.9375 10.0 0.84904 0.44179 
1.875 10.0 0.88255 0.32664 
3.75 10.0 0.90723 0.25857 
7.5 10.0 0.95114 0.12566 
15.0 10.0 0.99891 0.00110 
0.46875 20.0 0.90615 0.43901 
0.9375 20.0 0.91736 0.37542 
1.875 20.0 0.91584 0.39424 
3.75 20.0 0.95765 0.16806 
7.5 20.0 0.94714 0.24234 
15.0 20.0 0.97748 0.09058 
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Supplementary table 10. CI of vemurafenib (VEM) and metformin (MET) in NCI-
H508 
VEM (µM) MET Effect CI 
0.625 0.3125 0.22475 2.62875 
1.25 0.3125 0.13503 8.32378 
2.5 0.3125 0.25716 2.07034 
5.0 0.3125 0.21873 3.24244 
10.0 0.3125 0.59140 0.59297 
20.0 0.3125 0.86567 0.47039 
0.625 0.625 0.25416 3.85292 
1.25 0.625 0.23645 4.65866 
2.5 0.625 0.01504 1256.53 
5.0 0.625 0.17763 9.46419 
10.0 0.625 0.36691 2.12244 
20.0 0.625 0.73167 0.77016 
0.625 1.25 0.41558 1.96152 
1.25 1.25 0.59316 0.56032 
2.5 1.25 0.49434 1.19979 
5.0 1.25 0.51622 1.16856 
10.0 1.25 0.49802 1.58693 
20.0 1.25 0.77412 0.72361 
0.625 2.5 0.76688 0.23948 
1.25 2.5 0.73987 0.33069 
2.5 2.5 0.71295 0.46175 
5.0 2.5 0.61772 1.05014 
10.0 2.5 0.59657 1.43945 
20.0 2.5 0.79149 0.76092 
0.625 5.0 0.68764 0.95440 
1.25 5.0 0.71096 0.80168 
2.5 5.0 0.65018 1.38014 
5.0 5.0 0.56273 2.78266 
10.0 5.0 0.60023 2.35962 
20.0 5.0 0.73742 1.2731 
0.625 10.0 0.61642 3.37811 
1.25 10.0 0.59286 4.08566 
2.5 10.0 0.53161 6.54596 
5.0 10.0 0.59472 4.20161 
10.0 10.0 0.58914 4.61295 
20.0 10.0 0.78729 1.30486 
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Supplementary table 11. CI of panitumumab (PAN) and metformin (MET) in NCI-
H508 
PAN (nM) MET Effect CI 
0.01071 0.3125 0.03958 3.29196 
0.02143 0.3125 0.06185 3.51799 
0.04285 0.3125 0.21925 1.10097 
0.08571 0.3125 0.36566 0.85992 
0.17141 0.3125 0.52316 0.73658 
0.34283 0.3125 0.61458 0.88023 
0.01071 0.625 0.18798 0.52511 
0.02143 0.625 0.25892 0.55687 
0.04285 0.625 0.27747 0.84143 
0.08571 0.625 0.37114 0.91328 
0.17141 0.625 0.44314 1.1665 
0.34283 0.625 0.56037 1.22781 
0.01071 1.25 0.25277 0.55913 
0.02143 1.25 0.25857 0.7375 
0.04285 1.25 0.31366 0.86377 
0.08571 1.25 0.28728 1.59603 
0.17141 1.25 0.40372 1.5647 
0.34283 1.25 0.52849 1.56551 
0.01071 2.5 0.29897 0.82498 
0.02143 2.5 0.38253 0.79118 
0.04285 2.5 0.27351 1.38762 
0.08571 2.5 0.37862 1.34297 
0.17141 2.5 0.43877 1.62288 
0.34283 2.5 0.56816 1.55569 
0.01071 5.0 0.32081 1.44885 
0.02143 5.0 0.34892 1.49183 
0.04285 5.0 0.36905 1.62982 
0.08571 5.0 0.46410 1.57662 
0.17141 5.0 0.54067 1.63998 
0.34283 5.0 0.60301 1.83376 
0.01071 10.0 0.59040 1.97411 
0.02143 10.0 0.62138 1.92595 
0.04285 10.0 0.64644 1.90733 
0.08571 10.0 0.71220 1.7912 
0.17141 10.0 0.68805 1.99798 
0.34283 10.0 0.81715 1.63635 
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Supplementary table 12. CI of dasatinib (DAS) and metformin (MET) in HT29 
DAS (nM) MET (mM) Effect CI 
0.76 0.625 0.17735 1.04 
1.52 0.625 0.18933 1 
3.05 0.625 0.24009 0.81628 
6.1 0.625 0.16803 1.76 
12.2 0.625 0.21675 1.89 
24.4 0.625 0.33370 2.23 
0.76 1.25 0.36713 0.45598 
1.52 1.25 0.37823 0.48317 
3.05 1.25 0.38080 0.59066 
6.1 1.25 0.34141 0.96293 
12.2 1.25 0.41218 1.16 
24.4 1.25 0.49408 1.69 
0.76 2.5 0.37250 0.82488 
1.52 2.5 0.39520 0.77024 
3.05 2.5 0.42527 0.75353 
6.1 2.5 0.22607 2.96 
12.2 2.5 0.45283 1.26 
24.4 2.5 0.50521 1.82 
0.76 5.0 0.47017 0.86248 
1.52 5.0 0.49743 0.77860 
3.05 5.0 0.50379 0.84429 
6.1 5.0 0.46872 1.22 
12.2 5.0 0.55005 1.18 
24.4 5.0 0.66557 1.37 
0.76 10.0 0.48286 1.55 
1.52 10.0 0.52052 1.27 
3.05 10.0 0.53566 1.25 
6.1 10.0 0.52281 1.53 
12.2 10.0 0.57962 1.47 
24.4 10.0 0.67279 1.56 
0.76 20.0 0.66235 0.96566 
1.52 20.0 0.68987 0.83052 
3.05 20.0 0.68963 0.90046 
6.1 20.0 0.70961 0.92048 
12.2 20.0 0.72169 1.11 
24.4 20.0 0.79719 1.18 
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Supplementary table 13. CI of dasatinib (DAS) and metformin (MET) in RKO 
DAS (µM) MET Effect CI 
0.78 0.625 0.36741 0.66116 
1.56 0.625 0.36873 1.14 
3.12 0.625 0.37623 1.97 
6.25 0.625 0.59943 0.43827 
12.5 0.625 0.67605 0.37057 
25.0 0.625 0.99999 3.90E-6 
0.78 1.25 0.25265 2.47 
1.56 1.25 0.30780 2.37 
3.12 1.25 0.34580 2.88 
6.25 1.25 0.43518 2.21 
12.5 1.25 0.73648 0.23316 
25.0 1.25 0.9999 5.94E-5 
0.78 2.5 0.38235 1.03 
1.56 2.5 0.38841 1.39 
3.12 2.5 0.51404 0.82131 
6.25 2.5 0.59735 0.65865 
12.5 2.5 0.76000 0.25588 
25.0 2.5 0.999 9.05E-4 
0.78 5.0 0.45957 1.11 
1.56 5.0 0.51047 0.99901 
3.12 5.0 0.58314 0.81252 
6.25 5.0 0.65576 0.65323 
12.5 5.0 0.82186 0.25068 
25.0 5.0 0.98748 0.01705 
0.78 10.0 0.51629 1.61 
1.56 10.0 0.64366 1 
3.12 10.0 0.56934 1.5 
6.25 10.0 0.70615 0.84953 
12.5 10.0 0.78520 0.58729 
25.0 10.0 0.90419 0.23508 
0.78 20.0 0.63820 1.97 
1.56 20.0 0.68249 1.66 
3.12 20.0 0.69429 1.61 
6.25 20.0 0.81692 0.87869 
12.5 20.0 0.86543 0.63823 
25.0 20.0 0.9999 9.50E-4 
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Supplementary table 14. CI of regorafenib (REG) and metformin (MET) in HT29 
REG (µM) MET Effect CI 
0.0976 0.625 0.19536 2.08 
0.195 0.625 0.20173 2.01 
0.39 0.625 0.24625 1.43 
0.78 0.625 0.24933 1.62 
1.56 0.625 0.42127 0.96768 
3.12 0.625 0.56860 1.17 
0.0976 1.25 0.37682 0.86633 
0.195 1.25 0.32079 1.36 
0.39 1.25 0.31438 1.53 
0.78 1.25 0.32493 1.61 
1.56 1.25 0.37799 1.53 
3.12 1.25 0.59242 1.20 
0.0976 2.5 0.37196 1.74 
0.195 2.5 0.35990 1.95 
0.39 2.5 0.28355 3.65 
0.78 2.5 0.35251 2.34 
1.56 2.5 0.36945 2.46 
3.12 2.5 0.55516 1.55 
0.0976 5.0 0.45474 1.91 
0.195 5.0 0.46038 1.87 
0.39 5.0 0.44966 2.10 
0.78 5.0 0.47495 1.93 
1.56 5.0 0.46730 2.33 
3.12 5.0 0.60431 1.66 
0.0976 10.0 0.55684 1.86 
0.195 10.0 0.56316 1.81 
0.39 10.0 0.56316 1.88 
0.78 10.0 0.57351 1.89 
1.56 10.0 0.63125 1.55 
3.12 10.0 0.69462 1.52 
0.0976 20.0 0.73660 0.92910 
0.195 20.0 0.73188 0.99371 
0.39 20.0 0.76577 0.78269 
0.78 20.0 0.75290 0.97277 
1.56 20.0 0.79241 0.88217 
3.12 20.0 0.83850 0.94254 
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Supplementary table 15. CI of regorafenib (REG) and metformin (MET) in RKO 
REG (µM) MET Effect CI 
0.195 0.625 0.19052 0.59543 
0.39 0.625 0.15836 0.99607 
0.78 0.625 0.41852 0.49227 
1.56 0.625 0.49489 0.65820 
3.12 0.625 0.73191 0.52018 
6.25 0.625 0.9999 0.00116 
0.195 1.25 0.30707 0.54803 
0.39 1.25 0.31679 0.65531 
0.78 1.25 0.31266 0.92855 
1.56 1.25 0.56003 0.60744 
3.12 1.25 0.51253 1.24 
6.25 1.25 0.74911 0.96741 
0.195 2.5 0.37286 0.73753 
0.39 2.5 0.42951 0.68235 
0.78 2.5 0.53679 0.58577 
1.56 2.5 0.66108 0.52950 
3.12 2.5 0.54246 1.29 
6.25 2.5 0.91709 0.34859 
0.195 5.0 0.51356 0.81198 
0.39 5.0 0.45137 1.1 
0.78 5.0 0.37193 1.69 
1.56 5.0 0.61995 0.86780 
3.12 5.0 0.74396 0.75174 
6.25 5.0 0.87308 0.58466 
0.195 10.0 0.57473 1.24 
0.39 10.0 0.64475 0.99170 
0.78 10.0 0.70957 0.82252 
1.56 10.0 0.75928 0.75999 
3.12 10.0 0.82909 0.66801 
6.25 10.0 0.86342 0.77210 
0.195 20.0 0.78763 0.96501 
0.39 20.0 0.74501 1.22 
0.78 20.0 0.76885 1.14 
1.56 20.0 0.76905 1.24 
3.12 20.0 0.79085 1.29 
6.25 20.0 0.89738 0.79878 
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Supplementary table 16. CI of regorafenib (REG) and metformin (MET) in NCI-
H508 
REG (µM) MET Effect CI 
0.78 0.3125 0.16102 0.83768 
1.56 0.3125 0.18448 1.39 
3.12 0.3125 0.28676 1.56 
6.25 0.3125 0.36335 2.20 
12.5 0.3125 0.56444 1.93 
25.0 0.3125 0.98210 0.09484 
0.78 0.625 0.28842 0.42759 
1.56 0.625 0.19152 1.36 
3.12 0.625 0.23296 2.09 
6.25 0.625 0.31177 2.78 
12.5 0.625 0.50957 2.42 
25.0 0.625 0.86981 0.76305 
0.78 1.25 0.26515 0.52318 
1.56 1.25 0.42261 0.49617 
3.12 1.25 0.31699 1.42 
6.25 1.25 0.35417 2.34 
12.5 1.25 0.66917 1.28 
25.0 1.25 0.97280 0.15695 
0.78 2.5 0.22856 0.72369 
1.56 2.5 0.35938 0.71172 
3.12 2.5 0.41425 1.02 
6.25 2.5 0.44233 1.70 
12.5 2.5 0.51806 2.44 
25.0 2.5 0.99265 0.05809 
0.78 5.0 0.34739 0.61387 
1.56 5.0 0.42932 0.69668 
3.12 5.0 0.52666 0.80438 
6.25 5.0 0.59208 1.08 
12.5 5.0 0.62803 1.68 
25.0 5.0 0.91884 0.54579 
0.78 10.0 0.58685 0.55841 
1.56 10.0 0.62694 0.60709 
3.12 10.0 0.60537 0.84187 
6.25 10.0 0.70180 0.90249 
12.5 10.0 0.78027 1.02 
25.0 10.0 0.9999 0.01775 
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Supplementary table 17. CI of metformin (MET) and trametinib (TRA) in RKO 
MET (mM) TRA (nM) Effect CI 
0.625 2.0 0.24210 2.72152406 
1.25 2.0 0.34713 1.03152596 
2.5 2.0 0.47174 0.59930 
5.0 2.0 0.55458 0.63599 
10.0 2.0 0.71681 0.43285 
20.0 2.0 0.64300 1.39152916 
0.625 4.0 0.33743 1.49152145 
1.25 4.0 0.46960 0.50611 
2.5 4.0 0.51410 0.53260 
5.0 4.0 0.60225 0.50321 
10.0 4.0 0.91032 0.05936 
20.0 4.0 100152000 3.5E-10 
0.625 8.0 0.42636 1.02152311 
1.25 8.0 0.48238 0.68799 
2.5 8.0 0.60236 0.34373 
5.0 8.0 0.76069 0.16988 
10.0 8.0 0.86936 0.10970 
20.0 8.0 0.97170 0.02089 
0.625 16.0 0.53030 0.63604 
1.25 16.0 0.61106 0.32742 
2.5 16.0 0.68025 0.23292 
5.0 16.0 0.88048 0.04974 
10.0 16.0 0.91001 0.06068 
20.0 16.0 0.96988 0.02292 
0.625 32.0 0.60790 0.51529 
1.25 32.0 0.69671 0.21775 
2.5 32.0 0.68529 0.31326 
5.0 32.0 0.73851 0.27082 
10.0 32.0 0.77601 0.32286 
20.0 32.0 0.84216 0.31008 
0.625 64.0 0.49855 3.23152353 
1.25 64.0 0.62810 0.82466 
2.5 64.0 0.51672 2.92152760 
5.0 64.0 0.86104 0.08004 
10.0 64.0 0.91223 0.06202 
20.0 64.0 0.95836 0.03741 
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Supplementary table 18. CI of metformin (MET) and trametinib (TRA) in HT29 
MET (mM) TRA (nM) Effect CI 
0.625 0.03125 0.41507 0.80448 
1.25 0.03125 0.52401 0.53584 
2.5 0.03125 0.57145 0.64205 
5.0 0.03125 0.57090 1.24153662 
10.0 0.03125 0.61752 1.51153799 
20.0 0.03125 0.71779 0.97323 
0.625 0.0625 0.44215 0.69274 
1.25 0.0625 0.49612 0.75593 
2.5 0.0625 0.55138 0.82868 
5.0 0.0625 0.55843 1.45153817 
10.0 0.0625 0.63689 1.27153227 
20.0 0.0625 0.76038 0.58516 
0.625 0.125 0.43324 0.89727 
1.25 0.125 0.49221 0.90188 
2.5 0.125 0.49490 1.52153862 
5.0 0.125 0.51207 2.39153871 
10.0 0.125 0.59746 1.98153893 
20.0 0.125 0.71808 1.04153345 
0.625 0.25 0.47761 0.88563 
1.25 0.25 0.49999 1.07153622 
2.5 0.25 0.53262 1.29153554 
5.0 0.25 0.57217 1.54153051 
10.0 0.25 0.62977 1.58153328 
20.0 0.25 0.75232 0.77529 
0.625 0.5 0.61798 0.68677 
1.25 0.5 0.64310 0.67941 
2.5 0.5 0.67272 0.67984 
5.0 0.5 0.72337 0.60454 
10.0 0.5 0.77905 0.50090 
20.0 0.5 0.84648 0.33030 
0.625 1.0 0.63518 1.18153862 
1.25 1.0 0.61774 1.37153510 
2.5 1.0 0.65044 1.30153581 
5.0 1.0 0.69646 1.17153092 
10.0 1.0 0.76280 0.89800 
20.0 1.0 0.89004 0.32497 
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Supplementary table 19. CI of metformin (MET) and trametinib (TRA) in NCI-H508 
MET (mM) TRA (nM) Effect CI 
0.3125 0.0625 0.04260 9.35154192 
0.625 0.0625 0.22093 0.30234 
1.25 0.0625 0.14097 1.12154756 
2.5 0.0625 0.40646 0.37297 
5.0 0.0625 0.30580 1.19154793 
10.0 0.0625 0.58227 0.68411 
0.3125 0.125 0.02378 8.39154222 
0.625 0.125 0.04440 1.68154014 
1.25 0.125 0.12378 1.82154050 
2.5 0.125 0.18880 1.39154003 
5.0                       0.125 0.53749 0.41850 
10.0 0.125 0.79147 0.23306 
0.3125 0.25 0.21125 0.43317 
0.625 0.25 0.27354 0.30013 
1.25 0.25 0.28934 0.42289 
2.5 0.25 0.37957 0.44887 
5.0 0.25 0.48944 0.52146 
10.0 0.25 0.75697 0.28849 
0.3125 0.5 0.26436 0.37632 
0.625 0.5 0.27588 0.41633 
1.25 0.5 0.31201 0.44000 
2.5 0.5 0.37876 0.48638 
5.0 0.5 0.46674 0.59062 
10.0 0.5 0.69549 0.40413 
0.3125 1.0 0.37835 0.19518 
0.625 1.0 0.30553 0.48253 
1.25 1.0 0.40109 0.29910 
2.5 1.0 0.44844 0.37175 
5.0 1.0 0.55915 0.39889 
10.0 1.0 0.72695 0.34388 
0.3125 2.0 0.15152 7.31154300 
0.625 2.0 0.20735 2.87154569 
1.25 2.0 0.15761 7.03154876 
2.5 2.0 0.27059 1.75154582 
5.0 2.0 0.55628 0.42584 
10.0 2.0 0.72134 0.35777 
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CI Sinergy 
< 0.1 very strong synergy 
0.1-0.3 strong synergy 
0.3-0.7 moderate synergy 
0.7-0.85 slight synergy 
0.85-1 additivity 
> 1 antagonism 	
